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Summary
In November 2003, CDC and the Cystic Fibrosis Foundation cosponsored a workshop to review the benefits and risks associ-
ated with newborn screening for cystic fibrosis (CF). This report describes new research findings and outlines the recommenda-
tions of the workshop. The peer-reviewed evidence presented at the workshop supports the clinical utility of newborn screening for
CF. Demonstrated long-term benefits from early nutritional treatment as a result of newborn screening for CF include improved
growth and, in one study, cognitive development. Other benefits might include reduced hospitalizations and improved survival.
Mixed evidence has been reported for pulmonary outcomes. Newborn screening in the United States is associated with diagnosis
of CF a median of 1 year earlier than symptomatic detection, which might reduce the expense and anxiety associated with work-
up for failure to thrive or other symptoms. Certain psychosocial risks for carrier children and their families (e.g., anxiety and
misunderstanding) are associated with newborn screening. Exposure of young children to infectious agents through person-to-
person transmission in clinical settings, although not an inherent risk of newborn screening, is a potential cause of harm from
early detection. Involving specialists in CF care and infection control, genetic counseling, and communication can minimize these
potential harms. Although screening decisions depend on a state’s individual resources and priorities, on the basis of evidence of
moderate benefits and low risk of harm, CDC believes that newborn screening for CF is justified. States should consider the
magnitude of benefits and costs and the need to minimize risks through careful planning and implementation, including ongoing
collection and evaluation of outcome data.
Introduction
After sickle cell disease (SCD), cystic fibrosis (CF) is the
second most common life-shortening, childhood-onset inher-
ited disorder in the United States. Each year, approximately
1,000 persons in the United States receive a diagnosis of CF.
Whether screening newborn infants for CF should be recom-
mended on the basis of clinical benefit from early detection
has long been the subject of debate and scientific investiga-
tion (1,2). In 1979, development of a test to measure immu-
noreactive trypsinogen (IRT) in dried blood spots, which is
usually substantially elevated in newborns with CF, made
universal newborn screening for CF feasible (3). Pilot screen-
ing for albumin in meconium had previously been carried out
in certain European countries (4). The first newborn screen-
ing program for CF in the United States began in Colorado
in 1982, followed by Wisconsin in 1985 and Wyoming in
1988.
In 1997, CDC convened a workshop that reviewed the state
of scientific evidence on newborn screening for CF and for-
mulated recommendations (5). At that time, newborn screen-
ing for CF was conducted in those three states and in three
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other states (Connecticut, Montana, and Pennsylvania) in which
certain hospitals provided screening for CF as a clinical service.
Participants in the 1997 workshop found sufficient evidence
of nutritional benefit to recommend state-based demonstra-
tion screening projects (5). Because evidence regarding pul-
monary or other outcomes was limited, newborn screening
for CF was recommended for research purposes, with informed
consent and protocols for tracking and evaluating outcomes.
Research was to focus on 1) the consequences of delayed di-
agnosis, 2) cognitive development caused by malnutrition, 3)
pulmonary benefits, and 4) the cost-effectiveness of early de-
tection through screening. A subsequent workshop was to be
held to evaluate new evidence and, if warranted, to revise rec-
ommendations relating to newborn screening for CF.
In November 2003, in cooperation with the Cystic Fibrosis
Foundation (CFF), CDC held a second workshop in Atlanta,
Georgia. This workshop had three objectives: 1) to review and
evaluate the scientific evidence on benefits and risks of new-
born screening for CF; 2) to review screening, diagnostics,
and follow-up concerns in CF newborn screening decision
making; and 3) to disseminate information about models and
best practices for states that choose to adopt newborn screen-
ing for CF. The workshop was announced in the Federal
Register, and the proceedings are available online (http://
www.cdc.gov/ncbddd/cf/meeting.htm) (6). In addition, the
majority of the papers presented at the workshop will be pub-
lished in a CFF-sponsored supplement to the Journal of
Pediatrics.
Each state selects which disorders to include in its own new-
born screening panel (7,8). As of August 2004, the number of
disorders listed in state screening panels ranged from four to
40 (9). Criteria commonly used by states to decide on screen-
ing panels include the frequency of the disorder, the feasibil-
ity and accuracy of screening, the ability of early intervention
to improve outcomes, the availability of treatment, and the
cost of screening (10–12). Variability in screening criteria and
how they are applied indicates a need for evidence-based as-
sessments conducted at the national level (13). The traditional
screening criteria have been used to justify universal newborn
screening for disorders when early intervention is required soon
after birth to prevent death or severe disability, as with phe-
nylketonuria (PKU) (7). The application of these criteria to
other disorders with less evidence of overwhelming immedi-
ate benefit poses challenges. Alternative frameworks for evalu-
ating the balance of benefits and risks and approaches to
screening that mitigate the risks might need to be considered
for disorders such as CF (14).
This report summarizes findings presented at the 2003
workshop and those of other studies in the peer-reviewed lit-
erature. It also presents recommendations to advise states that
choose to adopt newborn screening for CF on how to maxi-
mize benefits and minimize harms in implementing screen-
ing. The information presented in this report is intended to
help decision makers reach informed policy decisions. In ad-
dition, this report might be of use to federal agencies, profes-
sional organizations, industry, academic institutions,
health-care providers, and the public.
Background
Genetics and Pathophysiology of CF
CF is an autosomal recessive genetic disorder; persons with
CF have mutations in the gene encoding for the cystic fibrosis
transmembrane conductance regulator (CFTR) protein on
both alleles of chromosome 7. Although >1,000 mutations
on the CFTR gene have been identified, a single common
mutation, ∆F508, accounts for two thirds of all CF alleles
worldwide (15,16). This mutation is particularly frequent in
persons of northern European ancestry, who also have the high-
est rates of CF, and is less common among persons of other
ancestries. Because different populations have different muta-
tion frequencies, the sensitivity of a given DNA mutation panel
for detecting persons with CF varies by race and ethnicity,
and including mutations specific to racial and ethnic minor-
ity populations can improve detection of CF among those
populations (16).
Because of differing frequencies of CFTR mutations, the
birth prevalence* of CF varies by race/ethnicity. On the basis
of data from U.S. newborn screening programs, birth preva-
lence is 1/2,500–3,500 births among non-Hispanic whites,
1/4,000–10,000 births among Hispanics, and 1/15,000–
20,000 births among non-Hispanic blacks (17–19). Non-
Hispanic whites, who in 2000 accounted for 56% of births in
the United States, constituted >90% of U.S. patients who re-
ceived a diagnosis of CF (20,21). On the basis of data from
state newborn screening programs that included CF in 2000,
the overall birth prevalence of CF in the United States is ap-
proximately 1/3,700 (21). It is more common than PKU (1/
20,000) and galactosemia (1/67,000) and less common than
congenital hypothyroidism (1/2,500) and SCD (1/2,600)†
(21).
Mutations in the CFTR gene can alter the structure, func-
tion, or production of a cyclic adenosine-5’-monophosphate
* The number of persons with CF at birth relative to the size of the birth
cohort, even though they might not receive a diagnosis until later, because
CF is a genetic condition.
† On the basis of data from states that reported confirmed results; however,
reporting is incomplete (21).
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(AMP)–dependent transmembrane chloride channel protein
that is critical for normal functioning of multiple organs. The
organs and systems that are affected in CF include the lungs
and upper respiratory tract, gastrointestinal tract, pancreas,
liver, sweat glands, and genitourinary tract (15). For example,
defective salt reabsorption in sweat glands leads to overly salty
sweat and, in certain cases, to electrolyte imbalance, dehydra-
tion, and death.
Deficient chloride transport in the lungs is thought to re-
sult in the production of abnormally thick mucus, which in
turn is believed to lead to airway obstruction, neutrophil-
dominated inflammation, and recurrent and progressive pul-
monary infections (15). The combination of inflammation
and infection accounts for the pulmonary symptoms related
to CF (4). Acute viral respiratory infections, common to all
children, are much more likely to develop into lower respira-
tory tract infections among children with CF, resulting in hos-
pitalization and acquisition of chronic bacterial infections
(22,23).
Pancreatic insufficiency, which results from virtually absent
pancreatic enzyme activity, is present at diagnosis among
>80% of persons with CF and increases with age to >90%.
Pancreatic insufficiency causes fat and protein malabsorption.
Gastrointestinal symptoms associated with fat malabsorption
include loose, foul-smelling fatty stools (steatorrhea) and ab-
dominal pain. Nutritional consequences of pancreatic insuf-
ficiency include fat-soluble vitamin deficiencies and growth
failure. Persons with CF who have normal or subnormal pan-
creatic enzyme activity, referred to as pancreatic sufficiency,
rarely experience nutrition-related symptoms but are at risk
for pancreatitis as they age (15). They also experience fewer
pulmonary problems and have lower mortality (24,25).
Research into genotype-phenotype associations in CF indi-
cates that both pancreatic insufficiency and pancreatic suffi-
ciency are associated with specific CFTR mutations. CFTR
gene mutations have been placed into five classes. The first
three are associated with complete loss of cyclic AMP-
regulated chloride channel function and are identified as “se-
vere” mutations. Mutations in the other two might allow for
residual CFTR function and therefore are usually associated
with milder phenotypes and pancreatic sufficiency (15,25).
Persons who have two mutations from within classes I, II, or
III almost invariably experience pancreatic insufficiency, and
those with <2 mutations from classes IV or V usually main-
tain pancreatic insufficiency (25). The common ∆F508 mu-
tation is a class II mutation that is associated with pancreatic
insufficiency. Not all CFTR mutations have been identified
or classified.
Natural History and Diagnosis of CF
The first symptom of CF in approximately 15%–20% of
children with CF is meconium ileus, an intestinal obstruction
present at birth that usually requires surgery to correct (15).
Children with meconium ileus have long-term adverse out-
comes (e.g., malnutrition, lung disease, and mortality) at rates
comparable to those for children detected later on the basis of
clinical symptoms (26). Because meconium ileus is diagnos-
tic of CF, screening does not increase early detection for these
children.
The most common symptoms of CF among children with-
out meconium ileus include recurrent cough, wheezing,
chronic abdominal pain, loose stools, and failure to thrive
(15,27). Failure to thrive is particularly common in infants
and young children. On the basis of data from the Wisconsin
randomized controlled trial of newborn screening for CF dur-
ing 1985–1994, the mean height-for-age Z-score at age 1 year
among children without screening results is approximately
–1.0, or 1 standard deviation (SD) below the reference mean
(28). With the introduction of nutritional therapies (e.g., pan-
creatic enzyme supplements and a high-fat diet) after a diag-
nosis of CF with pancreatic insufficiency, the majority of
children experience partial catch-up growth, and the mean
height-for-age Z-score settles around –0.4 by age 2 years.
Respiratory symptoms and infections increase with age. For
example, for a cohort of children with CF followed in Wis-
consin, the median age at which a pattern of frequent cough
became present was age 10.5 months, and 75% had chronic
cough by age 6 years (24). By age 7 years, 15%–25% of these
children had lung function below the normal range, with pro-
gressive decreases in lung function as the children aged (26,29).
Approximately 20% of children had positive cultures for
Pseudomonas aeruginosa, the leading respiratory pathogen in
CF, by age 1 year (30), but age at first acquisition varied widely.
In the Wisconsin study, among subjects followed at the center
that used recommended infection-control practices, the me-
dian age at first acquisition of P. aeruginosa was age 5 years
(29). Infection with mucoid P. aeruginosa leads to irreversible
pulmonary damage and death (31). In one cohort study, sur-
vival to age 16 years was 53% among children who had chronic
P. aeruginosa infections and 84% among those who did not
(32).
Mortality in CF is associated with chronic obstructive pul-
monary disease, with respiratory failure being the primary cause
of death among >90% of persons with CF (15). Until the
1980s, deaths typically occurred during childhood or adoles-
cence, but the majority of persons with CF now survive into
adulthood. During 1974–1994, the international median age
of death from CF increased from age 8 years to age 21 years
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(33). In the United States, the median age of death from CF
in 2000 was age 24 years, with 5% of deaths occurring before
age 10 years, 25% before age 17 years, and 75% before age 35
years (34). Because of increasing life expectancy, median age
of death understates survival; during 1969–2001, the median
predicted age of survival increased from age 14 years (35) to
age 33 years (20).
Early clinical recognition of CF on the basis of symptoms is
desirable but difficult because the majority of symptoms are
not specific to CF. Consequently, affected children often ini-
tially receive a diagnosis of food allergies, celiac disease, asthma,
or bronchitis rather than CF. Misdiagnoses can entail mul-
tiple office visits, unnecessary diagnostic tests and hospital-
izations, considerable cost to the health-care system, and
anxiety for parents. This process has been referred to as a
diagnostic odyssey, and narrative reports have documented re-
sulting parental distrust of and anger toward health-care pro-
viders (36).
The median age of diagnosis among all persons with CF in
the United States is age 5.3 months (interquartile range [IQR]:
0.7–38.0 months) (27). The overall median age at diagnosis
includes infants who receive a diagnosis of CF soon after birth
on the basis of meconium ileus, newborn screening, prenatal
screening, or a family history. The median age of clinical di-
agnosis on the basis of signs and symptoms other than meco-
nium ileus is 14.5 months (IQR: 4.2–65.0 months), compared
with 0.2 months (IQR: 0–0.9 months) for meconium ileus
and 0.5 months (IQR: 0–0.9 months) for newborn screening
(27). Diagnosis on the basis of symptoms among infants is
associated with a >2-fold greater risk of medical complica-
tions before diagnosis than diagnosis resulting from screening
(27). Delay between the appearance of CF-related symptoms
and diagnosis can result in adverse psychosocial effects for the
child’s family (36).
The traditional case definition for CF was based on a sweat
chloride level of >60 mEq/L from pilocarpine iontophoresis
(sweat test) and the presence of pulmonary disease or pancre-
atic insufficiency. Sweat testing consists of electrical-chemical
stimulation of skin to produce sweat, collection of sweat on
gauze pads or filter paper, and laboratory analysis of chloride
content in collected sweat. In 1999, a CFF consensus panel
developed a new case definition for CF based on multiple
criteria: the presence of >1 characteristic phenotypic feature
or a history of CF in a sibling or a positive newborn screening
test, together with laboratory evidence of a CFTR abnormal-
ity as documented by 1) elevated sweat chloride concentra-
tions, 2) identification of two CFTR mutations associated with
CF, or 3) in vivo demonstration of characteristic abnormali-
ties in ion transport across the nasal epithelium (37,15). Al-
though a sweat chloride level of 60 mEq/L is diagnostic, in-
fants with CF often have initial sweat values of 30–59 mEq/L
(38,39). Sweat testing can be performed accurately on the
majority of infants at age 2–3 weeks; however, not all infants
have sufficient quantities of sweat for reliable testing (40).
Classic CF, which usually manifests in early childhood, is
associated with lung disease and pancreatic insufficiency. Cer-
tain persons with mild CFTR dysfunction, who often receive
a diagnosis as adolescents or adults, are said to have nonclassic
or atypical CF (15), defined as having sweat chloride results
below the diagnostic level, milder phenotypic symptoms, and
two identified CFTR mutations, at least one of which is asso-
ciated with less severe disease (40). Sweat chloride levels in
infants of 30–59 mEq/L are ambiguous, because persons with
sweat chlorides in this range might have either classic or
nonclassic CF, or they might not have received a diagnosis of
CF (38,39). Because cohorts detected by screening might con-
tain more persons with nonclassic CF with milder phenotypes,
benefits of screening could be overstated. Ultimately, a better
understanding of the natural history of the disorder in infants
with two CFTR mutations and borderline or normal sweat
test results is needed to provide appropriate education, coun-
seling, treatment, and follow-up.
Treatment of CF
Children with diagnosed CF receive different treatments,
depending on the type of health-care facility and individual
characteristics. Children who are identified as having pancre-
atic insufficiency receive pancreatic enzymes and fat-soluble
vitamin supplements. Specialized CF centers vary in their ap-
proaches to the use of antibiotics for treatment and, in certain
places, prophylaxis of respiratory infections (41,42). Persons
with CF receive antibiotic treatment (oral, inhaled, or intra-
venous) for pulmonary exacerbations, characterized by in-
creased cough and sputum production. Regular microbiologic
monitoring and aggressive antibiotic treatment of infections
have been demonstrated to reduce the number of children
who experience chronic P. aeruginosa infections (43). Physio-
therapy and inhalation of nebulized mucolytics are also com-
mon components of treatment regimens. To receive optimal
treatment, children with CF should be examined at special-
ized CF centers that offer a comprehensive, multidisciplinary
approach to CF care and that can closely monitor the devel-
opment of respiratory infections and provide nutritional and
psychosocial support (4). CFF accredits a national network
of such centers, publishes clinical practice guidelines, and con-
venes consensus panels on CF care.
Changes in CF care since the early 1980s have included 1)
use of enteric-coated pancreatic enzymes to reduce the fre-
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quency of both gastrointestinal symptoms and nutritional
complications, 2) replacement of low-fat diets with high-fat
diets to offset the higher rates of fat malabsorption, 3) im-
proved mucolytics and airway clearance techniques, and 4)
use of more effective antibiotics to treat lung infections. These
changes have contributed to substantial improvements in
measures of malnutrition, lung function, and mortality among
children and adolescents with CF. For example, during 1985–
2001, predicted survival of persons with CF in the United
States increased from age 25 years to age 33 years (20). Dur-
ing 1985–1999, mortality rates for children aged 2–15 years
declined 45%–70%, mortality rates for persons aged 16–20
years were stable, and mortality rates for persons aged 21–40
years decreased 14%–20% (44).
Recent pharmacologic advances hold the promise of more
improvements in the health of persons with CF. For example,
palivizumab, a monoclonal antibody against respiratory syn-
cytial virus (RSV), has been demonstrated to be safe and ef-
fective in reducing RSV infections and hospitalizations among
infants and young children at high risk (45). Hospitalization
is one of the leading risk factors for the early acquisition of P.
aeruginosa (23). Since 1994, new approaches have become
available to slow the progression of pulmonary damage or to
treat pulmonary bacterial infections in persons with CF (e.g.,
recombinant human DNase, inhaled tobramycin, and
azithromycin) (46–49). Antibiotics and anti-inflammatory
drugs have been reported to slow decline in lung function
(31,50). Research is ongoing to determine the appropriate use
of such drugs in infants and young children. In addition, two
new therapies that directly target the mechanism of CF dis-
ease by improving chloride ion transport are in clinical trials
(Preston Campbell, M.D., Cystic Fibrosis Foundation, per-
sonal communication, May 3, 2004).
Prenatal Screening for CF
CF can be identified before birth through prenatal screen-
ing and after birth through newborn screening. In 2001, the
American College of Obstetricians and Gynecologists recom-
mended that pregnant women, especially those in higher-
prevalence populations defined by ethnicity, be offered
screening for CFTR mutations (51). Carrier couples can choose
prenatal diagnosis to determine whether a fetus has CF (de-
fined by the presence of each parent’s CF-associated muta-
tion). Carrier testing for CF is offered by an unknown number
of prenatal health-care providers. Preliminary data indicate
that <20% of pregnant women in the United States receiving
prenatal care are being screened for CF (52).
Both the 1997 and 2003 workshops restricted their focus
to newborn screening for CF as a state public health policy
and did not address prenatal screening. The coexistence of
two different screening programs for the same disorder de-
serves attention because of potential reciprocal effects and the
opportunity for coordination of information provision. Pre-
natal screening for CF in other countries is reported to have
led to a decrease in CF birth prevalence (53), but the majority
of infants with CF will not be detected through prenatal screen-
ing. The sensitivity of prenatal screening for CF among the
white population is <78% (54), much lower than that for
newborn screening, and the sensitivity of prenatal testing in
racial and ethnic minority populations is lower.§ Research is
needed to evaluate the effect in this country of offering carrier
testing in prenatal care on newborn screening and vice versa.
Newborn Screening for CF
As of 1997, three states (Colorado, Wisconsin, and Wyo-
ming) had universal newborn screening programs for CF, and
in three other states, screening was conducted at hospital dis-
cretion by a state public health laboratory (Montana), aca-
demic laboratories (Connecticut), or a commercial laboratory
(Pennsylvania) (55). During January 1998–April 2004, uni-
versal CF newborn screening was begun in four additional
states (Massachusetts, Mississippi, New York, and New Jer-
sey). Two more states (Oklahoma and South Carolina) are
expected to start universal screening for CF during 2004 (Table
1). In 2000, approximately 400,000 (10%) children born in
the United States were screened for CF; this number is ex-
pected to increase to 800,000 by the end of 2004 (12). Health-
care providers can also order testing from private laboratories
for disorders such as CF that are not included in state screen-
ing panels.
Screening Protocols and Algorithms
Multiple protocols and algorithms are used to screen new-
borns for CF (Table 1) (Box 1). All protocols begin with a
first-tier phenotypic test that measures IRT in dried blood
spots. Infants who have an elevated IRT measurement are then
referred for further testing. The specific value used to decide
whether IRT is sufficiently elevated to warrant further testing
varies. Different lab kits for IRT produce varying distribu-
tions of IRT measures, and screening programs set cutoffs on
the basis of evaluations of specimens from their own popula-
tions and the screening protocols and algorithms used
(Table 2). Screening programs in five states (Colorado, Con-
necticut, Montana, New Jersey, and Wyoming) set absolute
§ The sensitivity for carrier screening is lower because, to be identified as a
carrier couple, both parents must have a mutation included in the mutation
panel.
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cutoffs for a normal IRT value on the first newborn blood
spot (range: 90–105 ng/mL). Programs in four other states
(Connecticut, Massachusetts, New York, and Wisconsin)
classify as abnormal specimens in the top 4%–5% of IRT val-
ues for a given day or month, and programs in two states
(Mississippi and Pennsylvania) use the top 10% of daily IRT
values (55).
Programs in five states (Colorado, Connecticut, Montana,
South Carolina, and Wyoming) use an IRT-repeat IRT pro-
tocol. This protocol requires obtaining a second dried blood
spot specimen at approximately age 2 weeks. At this age, el-
evated IRT values are more specific for CF because IRT val-
ues decrease with age in infants without CF. In Colorado, a
routine second specimen is collected from all newborns,
whereas in the other states, an elevated IRT on the first speci-
men necessitates collection of a second specimen from those
infants. If the repeat IRT is elevated, with cutoffs varying
among states, the child is referred for sweat testing. A sweat
chloride of >60 mEq/L, confirmed by a second elevated sweat
test result, is considered diagnostic for CF (37), although in-
fants with CF might have lower sweat test results (38,56).
In eight states (Connecticut, Massachusetts, Mississippi,
New Jersey, New York, Oklahoma, Pennsylvania, and Wis-
consin), screening programs use an IRT/DNA algorithm in
which a single elevated IRT test is followed by DNA analysis
on the same blood spot specimen to detect >1 specific CFTR
mutation (55). Those newborns with a positive screening test
(i.e., elevated IRT test and >1 detected mutation) are usually
referred to a diagnostic center for a sweat chloride test to make
a definitive diagnosis, although children with two disease-
causing mutations are considered to have CF, regardless of the
results of the sweat test (37). The program in one state (New
Jersey) tests for only the common ∆F508 mutation although
second specimens are requested for a repeat IRT test if no
TABLE 1. States with newborn screening programs that include cystic fibrosis, by year begun, type of protocol, whether mandated,
and selected characteristics — United States, 1982–2004
State Year Protocol Comments
Colorado 1982 IRT*–repeat IRT Pilot program
1987 IRT–repeat IRT Population-based†
Wisconsin 1985 IRT–repeat IRT Pilot program, randomized trial
1991 IRT–DNA (∆F508) Pilot program, randomized trial
1994 IRT–DNA (∆F508) Population-based
2002 IRT–DNA (multiple mutations) Population-based
Wyoming 1988 IRT–repeat IRT Population-based, informed consent required
Montana 1992 IRT–repeat IRT Hospital-based§
Connecticut¶ 1993 IRT–repeat IRT Hospital-based
Connecticut** 1995 IRT– DNA (∆F508, multiple mutations) Hospital-based
Pennsylvania 1995 IRT–DNA (∆F508, multiple mutations) Hospital-based
Massachusetts 1999 IRT–DNA (multiple mutations) Pilot program, population based,
informed consent required
New Jersey 2001 IRT–DNA (∆F508 only) Population-based
New York 2002 IRT–DNA (multiple mutations) Population-based
Mississippi 2003 IRT–DNA (∆F508, multiple mutations) Population-based
Oklahoma†† Fall 2004 IRT–DNA (multiple mutations) Population-based
S. Carolina§§ Fall 2004 IRT–repeat IRT Population-based
Source: Wilfond BS, Gollust SE. Policy issues for expanding newborn screening programs: a look “behind the curtain” at cystic fibrosis newborn screening
programs in the United States [Presentation]. Newborn Screening for Cystic Fibrosis Meeting, Atlanta, Georgia, November 21, 2003.
* Immunoreactive trypsinogen.
† Screening offered to all infants in a state.
§ Screening provided to all infants born in selected hospitals.
¶ University of Connecticut.
** Yale University.
†† Projected date (Source: Pamela King, M.P.A., Oklahoma State Department of Health, Oklahoma City, Oklahoma, personal communication, March 15,
2004).
§§ Projected date (Source: Kathy Tomashitis, M.N.S., South Carolina Department of Health and Environmental Control, Columbia, South Carolina, personal
communication, March 15, 2004).
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Action after Result of Result of Result of
elevated DNA assay repeat DNA IRT assay
IRT* on 1st on 1st assay on 1st on 2nd
Protocol specimen specimen Action specimen Action specimen Action
IRT-repeat Test 2nd Exceeds Refer to
IRT specimen for cutoff sweat test
IRT
IRT-DNA DNA assay 1–2 Refer to sweat
(∆F508) for ∆F508 mutations test
alleles detected
No mutation Exceeds Refer to
detected cutoff sweat test
IRT-DNA DNA assay 1–2 Refer to sweat
(multiple for multiple mutations test
mutations) mutations detected
IRT-DNA DNA assay 2 mutations Refer to sweat 2 mutations Refer to sweat
(∆F508, for ∆F508 detected test or treatment detected test or treatment
multiple alleles
mutations) 1 mutation DNA assay 1 mutation Inconclusive
detected for multiple detected result reported
mutations
* Immunoreactive trypsinogen.
BOX 1. Screening protocols for cystic fibrosis
mutation is detected. Programs in three other states (Con-
necticut, Mississippi, and Pennsylvania) test first for the ∆F508
mutation and, if one ∆F508 mutant allele is detected, apply a
multiple-mutation panel to screen for other mutations. Pro-
grams in the remaining four states (Massachusetts, New York,
Oklahoma, and Wisconsin) use or plan to use a multiple-
mutation panel to test all specimens with an elevated IRT.
Programs in all seven states (Connecticut, Massachusetts,
Mississippi, New Jersey, New York, Pennsylvania, and Wis-
consin) that have implemented IRT-DNA algorithms also
include a protocol that identifies infants without an identi-
fied mutation but with a highly elevated IRT value as being at
risk for CF, because a child might have mutations for which a
test is not administered. The cutoff of a highly elevated IRT is
variable; cutoffs representing an IRT value of 99.8% or 99.9%
of screened newborns or absolute values of 130, 170, or 200
ng/mL are used in different programs (55). Programs in three
states (Massachusetts, New Jersey, and New York) treat such
infants as positive screens and request that they be referred for
sweat testing unless a repeat specimen with a normal IRT is
first received. Programs in the remaining four states (Con-
necticut, Mississippi, Pennsylvania, and Wisconsin) report the
results but do not request referrals for sweat testing (55).
Screening programs that use mutation testing as part of their
screening algorithm can choose from commercially available
reagents for detection of multiple mutations (17,57), all of
which have been developed to address the prenatal testing
market’s response to recommendations from the American
College of Medical Genetics (ACMG) (58). The ACMG panel
was chosen on the basis of the relative frequency of CFTR
mutations among U.S. residents with CF (58) but did not
take into account genotype-phenotype associations among per-
sons with varying levels of severity of CF (25) or mutations
detected with high frequency among certain racial/ethnic
populations (59). Inclusion of a greater number of CFTR mu-
tations in newborn screening panels will increase the number
of persons identified as carriers and the numbers receiving
either an ambiguous diagnosis of CF or a diagnosis of classic
CF (17). Determination of which mutations should be in-
cluded in panels for newborn screening should be developed
by a workgroup of newborn screening specialists and persons
with CF expertise.
Analytic Validity
The analytic validity of testing indicates the extent to which
laboratory test results are reported accurately. Certain ana-
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lytic errors might be detected through program follow-up; for
example, during 21 years of screening, the Colorado program
has reported four false-negative screens resulting from labora-
tory errors among 1,153,339 live births (18). To monitor ana-
lytical validity on an ongoing basis, newborn screening
laboratories should participate in a proficiency testing pro-
gram. Starting in 2002, CDC implemented a proficiency test-
ing program for monitoring laboratory performance in testing
IRT and ∆F508 mutations in newborn dried blood spots (60).
A separate proficiency testing program for clinical laborato-
ries performing CF carrier testing by using multiple mutation
panels is also available (61).
Clinical Validity
The clinical validity of a screening test refers to the ability
of a test to detect a person with a particular disorder. Deter-
mination of the clinical validity of a screening test requires
the ascertainment of missed cases detected clinically as well as
TABLE 2. Clinical sensitivity of newborn screening for cystic fibrosis
IRT* DNA Direct referral Reported
No. cutoff on first testing used of ultrahigh clinical sensitivity
State Years covered screened specimen for screening IRT (excluding MI†)
Colorado§ 1982–1987 279,399 140 ng/mL No NA¶ 93%
Colorado**†† 1988–2002 873,940 105 ng/mL No NA 95%
(since 2000)
Wisconsin§§ 1988–1991 220,862 180 ng/mL No NA 87%
Wisconsin§§ 1991–1994 104,308 110 ng/mL ∆F508 only No 94%
Wisconsin¶¶ 1994–2002 509,794 96% of daily ∆F508 only No††† 94%
average***
Wisconsin¶¶ 2002–2003 90,142 96% of daily 25 mutations No††† 95% (99%)§§§
average
Massachusetts 1998–2003 323,506 95% of monthly 1999–2002: IRT >99.8% 99%
(observed)¶¶¶ average 16 mutations; referred
2002–2004:
25–27 mutations
Massachusetts¶¶¶**** 1998–2003 323,506 95% of monthly 1999–2002: No 96%
(assuming no direct average 16 mutations;
referral of ultrahigh 2002–2004:
IRT) 25–27 mutations
Massachusetts¶¶¶**** 1998–2003 323,506 95% of monthly ∆F508 only No 86%
(assuming single average
mutation testing and no
direct referral of
ultrahigh IRT)
* Immunoreactive trypsinogen.
† Meconium ileus.
§ Source: Hammond KB, Abman SH, Sokol RJ, Accurso FJ. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentra-
tions. N Engl J Med 1991;325:769–74.
¶ Not applicable; referral of infants with ultrahigh IRT values despite no mutation detected is relevant only to IRT/DNA screening protocols.
** Source: Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Immunoreactive trypsinogen-based newborn screening for cystic fibrosis in
Colorado: recall rate, genotyping and borderline sweat test results. J Pediatr (suppl) (in press).
†† Data for 1982–1987 are subtracted from the cumulative numbers for 1982–2002 presented in Holtzman NA. Routine screening for cystic fibrosis: not yet.
Pediatrics 1984;73:98–9.
§§ Source: Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
Pediatrics 1997;99:819–24.
¶¶ Source: Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine years’ experience
with routine trypsinogen/DNA testing. J Pediatr (suppl) (in press).
*** During 1994–1999, Wisconsin set the IRT cutoff at the 94th percentile, which was changed to the 96th percentile in 1999. No cases detected during 1994–
1999 declined between the 94th and 96th percentiles.
††† Wisconsin reports children with IRT >99.9% and without a detected mutation as “possible abnormal” but does not refer patients for sweat testing. Half of
false-negatives during 1994–2002 were in this category.
§§§ Observed sensitivity was 95% on the basis of a limited number of cases; predicted sensitivity for the new algorithim was 99%.
¶¶¶ Source: Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is
incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics 2004;113:1573–81.
**** Calculations projected for hypothetical screening protocols on the basis of the numbers of cases that presumably would have been detected on the basis
of observed values by using a more comprehensive protocol.
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the tracking of final diagnostic status of all those with positive
screens. Newborn screening algorithms for CF routinely re-
sult in false-negatives (62). Certain persons with CF either
have IRT values below the cutoff used for screening (63) or
are missed in the DNA stage of IRT/DNA screening because
they do not have a mutation included in the mutation panel
used by the screening program. Data on the clinical sensitiv-
ity of newborn screening for CF from screening programs in
the United States have been published (Table 2). Children
with meconium ileus might have low IRT values and be missed
by screening but are detected soon after birth anyway (4);
90%–95% of children with CF without meconium ileus are
reported to be detected by IRT-repeat IRT screening (64–
66,18). IRT/DNA screening and follow-up protocols that use
multiple mutation panels and directly refer children with ex-
tremely high IRT values for sweat testing have achieved clini-
cal sensitivity of >98% (17).
The number of false-positive¶ results in newborn screening
tests for conditions other than CF is often >50 times the num-
ber of cases of diagnosed disease (64). In comparison, the
number of false-positive results from newborn screening for
CF is moderate. Among states using IRT/DNA algorithms,
the ratio of false-positive screens to true-positive cases is re-
ported to be 9.5:1 in Wisconsin (57), 12:1 in Massachusetts
(67), and 25:1 in New York (Kenneth A. Pass, Ph.D., New
York State Department of Health, personal communication,
August 19, 2004) (Table 2). In Colorado, which performs
repeat IRT measures on two specimens, five false-positive CF
screening results are reported for every true-positive, whereas
if positive results had been reported based on an elevated IRT
value from the initial specimen, the average ratio of false-
positives to true-positives would have been 30:1 (18).
Although the number of false-positive screens for CF is rea-
sonable relative to other newborn screening tests, screening
for CF carries an additional responsibility for providing ge-
netic counseling to families of screen-positive children who
actually carry a CFTR mutation despite having a negative di-
agnostic test. Reporting of CF carrier status is one outcome of
newborn screening, which has the potential to be both a ben-
efit and a risk for families of carriers. Because newborn screen-
ing identifies considerably more carriers than children with
CF, benefits and harms to families of carriers should be con-
sidered in assessing newborn screening for CF.
Costs
The laboratory cost of CF newborn screening varies with
the screening algorithm but is comparable to that of newborn
screening tests in common use (64). Data from the Wiscon-
sin screening program indicate that the laboratory cost of IRT
screening is $1.50/test, the cost of a single-mutation analysis
is $20.50, and the cost of a multiple-mutation test is $50.70
(68). These numbers yield average costs of $2.35 for an IRT/
DNA algorithm with a single mutation and $3.60 for an IRT/
DNA algorithm with a multiple-mutation panel. A full ac-
counting of the costs of implementing newborn screening for
CF would require additional information on the costs of fol-
low-up, diagnosis, counseling, and providing care. In addi-
tion, averted diagnostic and treatment costs, if any, should be
factored in. A preliminary analysis indicates that averted di-
agnostic costs could cover the majority of initial screening
costs (69).
Scientific Evidence
Selection of Studies
In preparation for the workshop, CDC searched the
MEDLINE® database of medical literature for articles on new-
born screening for CF published since the 1997 workshop
that discussed health outcomes or psychosocial outcomes in
groups of children identified with CF through newborn screen-
ing in comparison with children identified through other
means. In addition, review articles were obtained and refer-
ence lists searched to identify additional articles. Subsequently,
a decision was made to include findings from previously pub-
lished studies, which were identified by searches of reference
lists.
An analytic framework was developed that modeled indi-
rect links from newborn screening to nutritional status and
from nutritional status to lung function and survival (Fig-
ure). Accordingly, a literature search was also conducted to
locate studies of associations between nutritional status among
children and adolescents with CF and lung function or sur-
vival outcomes. This search used the MEDLINE® database
and soliciting of specialists for additional studies.
A planning committee for the workshop identified research-
ers worldwide examining outcomes in relation to newborn
screening for CF. At least one person from each research study
group was invited to present the study’s findings at the 2003
workshop. Certain presentations were based on research that
had already been accepted for publication or was in press. In
addition, CFF decided to cosponsor a peer-reviewed supple-
¶ Refers to persons with a positive screening result who do not receive a diagnosis
of disease. A positive screening result might provide useful information even
absent a diagnosis. Infants with a positive screening result for CF identified
using an IRT/DNA algorithm who do not receive a diagnosis of CF are
carriers with one CFTR mutation (17).
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Intervention
Benefits
Detection of disease—
Identify children with CF
Shorten diagnostic period
Psychosocial and
reproductive benefits
for families
Benefits
Disease-oriented outcomes—
Micronutrient deficiencies
Benefits
Patient-oriented outcomes—
Cognitive function
Harms
Screening
Harms
Population at risk
Physical growth
Lung function and status
Mortality
Health-related quality of life
Hospitalizations
and treatments
False-positives — Parental anxiety
False-negatives — Delay in diagnosis
Misinformation or misunderstanding
Unwanted knowledge of carrier status
Person-to-person transmission
of infections in clinical settings
Potential treatment toxicities
Newborns
FIGURE. Potential benefits and harms of newborn screening for cystic fibrosis (CF)
ment to the Journal of Pediatrics to which presenters were in-
vited to submit papers for publication; 15 papers cited in this
report are scheduled for publication in that supplement.
Analytic Framework for Evaluating
Effects of CF Newborn Screening
To evaluate the potential benefits and risks of newborn
screening for CF, CDC applied an analytic framework to in-
terpret evidence of clinical utility (i.e., the net balance of health
outcomes) of earlier identification and treatment (Figure). This
framework draws in part on the approach used by the U.S.
Preventive Services Task Force (USPSTF) (70). It considers
both potential benefits and harms from screening; harms are
classified separately as adverse effects from screening and those
from diagnosis or treatment. The benefits of screening flow
from early, asymptomatic detection and can be classified in
terms of health benefits to the affected person and psychoso-
cial benefits to persons and families. To classify health ben-
efits, CDC used the Strength of Recommendations Taxonomy
(SORT), a recently proposed patient-centered approach to
grading evidence in medical literature (Box 2) (71). The SORT
framework does not include psychosocial outcomes, which
constitute key benefits and risks from newborn screening for
CF and should be considered in policy recommendations.
The potential psychosocial risks of screening include fac-
tors associated with 1) false-positives (e.g., unnecessary test-
ing and possibly unnecessary treatment for the child, undue
parental anxiety, and desensitization of providers), 2) false-
negatives (e.g., potential delay in diagnosis for child and false
reassurance for patients), 3) carrier reporting (e.g., possibly
unwanted information and fear of stigmatization or insur-
ance discrimination), and 4) misinformation (e.g., errors in
communication or misunderstanding of results). Potential
harms to CF patients of early detection and treatment as a
result of newborn screening include side effects of therapies
(e.g., drug resistance and toxicities) and earlier exposure
(through person-to-person transmission from older children
with CF) to bacteria associated with chronic airway infection
in CF.
The SORT taxonomy is used to assess the clinical effective-
ness of interventions based on a structured review of research
findings (71). The SORT framework categorizes studies into
three levels (Levels 1, 2, and 3) on the basis of study design
and type of outcomes assessed. The total evidence for an in-
tervention is given one of three grades (A, B, or C) on the
basis of the assigned levels of the individual studies.
The SORT taxonomy distinguishes two classes of health
outcomes: 1) disease-oriented outcomes (e.g., intermediate, his-
topathologic, physiologic, or surrogate results) that might re-
flect improvements in patient outcomes and 2) patient-oriented
outcomes (e.g., reduced morbidity, reduced mortality, symp-
tom improvement, improved quality of life, or lower cost)
that help patients live longer or better lives (71).
In the SORT framework, either a high-quality randomized
controlled trial (RCT) or a meta-analysis of RCTs that dem-
onstrates improved patient-oriented outcomes is considered
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BOX 2. Strength of Recommendation Taxonomy (SORT)
Consistency across studies
Level Definition
A Recommendation based on consistent and good-quality patient-oriented evidence*
B Recommendation based on inconsistent or limited-quality patient-oriented evidence
C Recommendation based on consensus, usual practice, opinion, disease-oriented evidence,† and case series for
studies of diagnosis, treatment, prevention, or screening
Type of study
Treatment/Prevention/
Study quality Diagnosis Screening Prognosis
Level 1: high-quality
patient-oriented evidence
• Validated clinical decision
rule
• Systematic review (SR)/
meta-analysis of high-
quality studies
• High-quality diagnostic
cohort study§
• SR/meta-analysis of
randomized control trials
(RCTs) with consistent
findings
• High-quality individual
RCT¶
• All or none study**
• SR/meta-analysis of
high-quality cohort
studies
• Prospective cohort study
with good follow-up
Level 2: limited-quality
patient-oriented evidence
• Unvalidated clinical
decision rule
• SR/meta-analysis of lower-
quality studies or studies
with inconsistent findings
• Lower-quality diagnostic
cohort study or diagnostic
case-control study
• SR/meta-analysis of lower-
quality clinical trials or
studies with inconsistent
findings
• Lower-quality clinical trial
• Cohort study
• Case-control study
• SR/meta-analysis of
lower-quality cohort
studies or studies with
inconsistent results
• Retrospective cohort
study or prospective
cohort study with poor
follow-up
• Case-control study
• Case series
Level 3: other evidence Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented
evidence (intermediate or physiologic outcomes only), and case series for studies of diagnosis, treat-
ment, prevention, or screening
Consistent • Majority of studies reported similar or at least coherent conclusions (i.e., differences are explainable),
or
• If high-quality and up-to-date systematic reviews or meta-analyses exist, they support the recom-
mendation.
Inconsistent • Considerable variation among study findings and lack of coherence, or
• If high-quality and up-to-date systematic reviews or meta-analyses exist, they do not find consistent
evidence in favor of the recommendation.
Source: Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical
literature. J Am Board Fam Pract 2004;17:59–67.
* Measures outcomes that matter to patients: morbidity, mortality, symptom improvement, cost reduction, or quality of life.
† Measures intermediate, physiologic, or surrogate endpoints that might reflect improvements in patient outcomes (e.g., blood pressure, blood chemistry,
physiologic function, and pathologic findings).
§ That is, cohort design, adequate size, adequate spectrum of patients, blinding, and a consistent, well-defined reference standard.
¶ Allocation concealed, blinding if possible, intention-to-treat analysis, adequate statistical power, and adequate follow-up (i.e., >80%).
** One in which the treatment causes a dramatic change in outcomes (e.g., antibiotics, meningitis, or surgery for appendicitis) that precludes study in a
controlled trial.
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Level-1 evidence. Information on patient-oriented outcomes
from a lower-quality clinical trial, cohort study, or case-
control study constitutes Level-2 evidence. All other types of
research studies, including case series, are classified as Level 3,
along with all studies, even RCTs, that provide information
restricted to disease-oriented outcomes.
For the SORT framework to be applied, endpoints used in
evaluations of newborn screening for CF are classified as ei-
ther patient-oriented or disease-oriented. The approach taken
in this report is to classify endpoints that are collected during
routine clinical monitoring of individuals with CF as disease-
oriented outcomes. These include measures of nutritional and
pulmonary outcomes (e.g., height and weight, spirometric
measures of lung function, and chest radiograph scores). In
this analysis, survival, quality of life, and cost (including hos-
pitalizations and invasive therapies) were classified as patient-
oriented outcomes. Cognitive function, which is not routinely
assessed in persons with CF, was also classified as a patient-
oriented outcome because of its direct link to quality of life
and because it is not a surrogate outcome in CF. The classifi-
cation of certain endpoints as disease-oriented or patient-
oriented outcomes has implications for assessment of evidence
on newborn screening for CF. In particular, growth retarda-
tion might be regarded as both a patient-oriented outcome
and a disease-oriented outcome. The high demand for expen-
sive growth hormone therapy, which results in moderate gains
in linear growth for children with CF who have low height-
for-age (72,73), indicates that below-normal stature might be
viewed as a patient-oriented outcome. In addition, growth
retardation among children with CF has been demonstrated
to be a strong predictor of survival. An RCT indicating re-
duction in growth retardation would be classified as Level-1
evidence if this outcome were classified as patient-oriented
but as Level-3 evidence if it were classified as disease-oriented.
The SORT approach integrates the strength of evidence
approach (74) with the type of health outcomes considered in
establishing a hierarchy of evidence (71). In the SORT tax-
onomy, an A-level recommendation requires consistent and
high-quality, patient-oriented evidence, including consistent
findings from at least two high-quality randomized controlled
trials. A B-level recommendation requires patient-oriented
evidence (i.e., an improvement in morbidity, mortality, symp-
toms, quality of life, or cost) based on Level-1 or Level-2 evi-
dence. A C-level recommendation is based on evidence relating
to disease-oriented outcomes from any type of study or for
patient-oriented outcomes from other types of observational
studies, case series, or opinions of specialists (71). A limita-
tion of the SORT framework for evaluating the overall strength
of evidence for newborn screening tests is the scarcity of RCTs.
CF is the only condition for which two RCTs of newborn
screening have been conducted. This puts newborn screening
at a disadvantage, with a B-level recommendation realistically
the highest that can be assigned to any newborn screening test
by using this framework.
This report summarizes what is known about the strength
of evidence for health benefits of newborn screening for CF,
including assessments of the strengths and limitations of study
designs and the consistency and magnitude of benefits re-
ported. However, the report is not a formal systematic evi-
dence review that would form the basis for an evidence-based
practice guideline (70,71,74,75). Systematic reviews involve
a lengthy process in which teams of reviewers conduct struc-
tured reviews with blinded assessments of study quality. The
only newborn screening tests endorsed by USPSTF on the
basis of systematic reviews are for PKU, congenital hypothy-
roidism, and hemoglobinopathies (75).
Evidence for Benefits
Sources of Data
Information to assess the effect of newborn screening for
CF on health benefits for children with CF is available from
three types of investigations: 1) RCTs of newborn screening,
2) geographic and temporal comparisons of screened and
unscreened cohorts, and 3) assessments of outcomes of per-
sons with CF reported to registry databases. The methods of
two randomized trials of newborn screening for CF and four
observational studies comparing health outcomes among
screened and unscreened cohorts are summarized (Table 3).
RCTs
The Wisconsin CF Neonatal Screening Project randomly
assigned neonates born in Wisconsin during 1985–1994 to
either a screened or control group (28,76) (Table 3). Neona-
tal CF screening was performed on blood spots from all sub-
jects, but positive results were reported only to families in the
screened group. Positive results were released to families in
the control group if any of the following occurred: 1) parents
requested the results, 2) CF was diagnosed conventionally, or
3) the child reached age 4 years and a diagnosis of CF had not
been established. Subjects with a diagnosis of CF in both
groups were entered (after informed consent) into a longitu-
dinal protocol that specified evaluation methods and stan-
dardized therapeutic interventions. Caregivers and investigators
were blinded to group identity after the first visit. The study
protocol included follow-up after diagnosis with CF every 6
weeks during the first year of life and every 3 months thereaf-
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ter, through age 17 years. All children received care at one of
two CFF-accredited care centers.
The Wisconsin RCT had two key limitations, both of which
could lead to underestimation of the magnitude of health ben-
efits of screening in that study. First, despite randomization
of study subjects, substantially more subjects with ∆F508
alleles (p<0.05) or pancreatic insufficiency (p<0.05) were
identified in the screened group (77). Second, during the first
6 years of the study, premature acquisition of P. aeruginosa
occurred among screened children who were followed at one
of the two CF care centers participating in the study that had
a small, crowded waiting room in which infants and older
children with established infections mixed (30). The median
pseudomonas-free period was 52 weeks among screened in-
fants seen at the first center and 289 weeks among those fol-
lowed up at the second center, which segregated children
enrolled in the study from other patients (76).
In the United Kingdom, all neonates born in Wales and the
West Midlands during 1985–1989 were randomly allocated
to undergo or not undergo CF screening on an alternate-week
basis (78) (Table 3). Because no screening was performed in
the control group, an unknown number of undiagnosed cases
of CF in this group were not ascertained. A review of registry
data revealed previously unknown CF-related deaths among
children in the unscreened group (79). No specific treatment
and follow-up protocol existed in the study. Children who
TABLE 3. Characteristics of studies of health outcomes in screened (S) and unscreened cohorts of children with cystic fibrosis
(CF)
No. in screened No. in unscreened Follow-up
Study location and reference cohort* cohort† Screening period§ (yrs)
Randomized controlled trials
Wisconsin CF Neonatal Screening 56** 48** 1985–1994 16
Project, United States¶
Wales/West Midlands, United 58 (12) 44 (7) 1985–1989 4
Kingdom††
Comparisons of screened
and unscreened cohorts
New South Wales/Australia 60 57 Screened: 1981–1984 15
(historic controls)§§ Unscreened: 1978–1981
Netherlands (geographic controls 24 (18) Unscreened: 29 (24) Screened: 1973–1979 17
and historic controls)¶¶ Postscreened: 39 (30) Unscreened: 1973–1979
Postscreened: 1979–1985
France: Brittany versus Loire– 77 36 1989–1998 10
Atlantique***
Italy: Veneto/Trentino versus Friuli 58 Meconium ileus: 45 1973–1981 —
Venezia Giulia/Romagna††† Pancreatic insufficiency: 75
Pancreatic sufficiency: 19
Italy: Veneto versus Sicily††† 126 (Veneto)§§§ 152 (Sicily)§§§ 1983–1992 —
* Numbers of subjects for whom data were available at age 4 years are in parentheses.
† Numbers of subjects for whom longitudinal follow-up data were available are in parentheses.
§ Substantive improvements in CF care were introduced in the 1980s, including phase-out of low-fat diets, introduction of enteric-coated pancreatic en-
zymes, and more aggressive antibiotic therapies, including inhaled antibiotics.
¶ Sources: Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves
long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001;107:1–13. Farrell PM, Li Z, Kosorok MR, et al. Bronchop-
ulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003;168:1100–8.
** Includes only patients without meconium ileus.
†† Source: Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years
of screening. Arch Dis Child 1991;66:29–33.
§§ Sources: Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 1985;2(8468):1319–21.
McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr (suppl)
(in press).
¶¶ Source: Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical
outcome and survival of CF patients. Eur Respir J 2001;18:306–15.
*** Source: Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed
from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 2003;35:342–9.
††† Source: Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 2001;1:531–7.
§§§ Includes all patients in each region. The majority of subjects in Veneto received diagnoses by newborn screening.
14 MMWR October 15, 2004
received a diagnosis of CF through screening were supposed
to be followed annually at a CF care center until age 5 years;
however, a substantial number of unscreened children with
CF did not receive care at a CF care center (79).
Underascertainment in the control group, lack of standard-
ized treatment protocols, and short, uneven follow-up indi-
cate that this is a lower-quality clinical trial that would yield
Level-2 rather than Level-1 evidence.
Cohort Studies
An observational study in Australia compared outcomes
among children with CF born in New South Wales during
the 3 years before the introduction of CF newborn screening
in July 1981 (and who therefore received a diagnosis conven-
tionally) with those born during July 1981–July 1984 (80–
82) (Table 3). All analyses were conducted on an intent-to-treat
basis, with children included in the screened cohort if they
were born while screening was offered, regardless of mode of
diagnosis. All subjects were followed at a single CF clinic.
Clinical data were collected retrospectively from medical
records at diagnosis and ages 1, 5, 10, and 15 years. Changes
in clinical practice over the 16 years of the study might have
influenced comparisons. Improved nutritional practices in-
troduced during 1981–1983 could potentially have biased
outcomes in favor of screening (81).
A pilot study used the albumin content of meconium to
screen for CF in approximately half (45%) of all newborns
born during 1973–1979 in a defined area in the northern
Netherlands (83). Screening was not random; providers de-
cided whether to offer screening, and parents could decide
whether to participate. Investigators compared outcomes of
the screened cohort (S) with two cohorts of children who re-
ceived diagnoses clinically: one that received a diagnosis at
the same time as the screened group (non-S) and one that
received a diagnosis in the 6 years after the pilot screening
project was discontinued (post-S) (83–85). CF care was pro-
vided at a local hospital with (54%) or without (46%) semi-
annual to annual visits at a specialized CF center. Follow-up
and therapeutic protocols were not standardized. Clinical data
were collected prospectively for 1980–1990 and retrospectively
for 1990–1997, after an intent-to-treat analysis (85,86). The
post-S group is not subject to selection bias, which might char-
acterize the non-S group. More confidence can be placed in
findings consistent for both comparison groups.
An observational study from France compared children with
CF born during 1989–1998 in Brittany, which screened new-
borns for CF, with a comparison group of newborns in a neigh-
boring region, Loire-Atlantique, which did not implement
screening for CF and had comparable CF care (87) (Table 3).
Standardized follow-up was provided for patients who received
a diagnosis of CF, including monthly clinic visits for the first
6 months after diagnosis and quarterly clinic visits thereafter.
Therapeutic management was standardized. Differential
underascertainment did not appear to be a major problem in
this study, because the same birth prevalence was observed in
both areas. Primarily because of differing population size, the
S cohort (n = 77) was larger than the non-S cohort (n = 36).
The intent-to-treat principle was not followed because false-
negative screening results (n = 5) were excluded from the S
cohort; however, the limited number of excluded patients is
unlikely to have affected the conclusions. In addition, the ex-
clusion of children with meconium ileus in Brittany (n = 14)
and Loire-Atlantique (n = 10) affected the two cohorts dis-
proportionately.
Data from northeastern Italy have been used to compare
outcomes among persons with CF detected by screening and
symptoms. One analysis compared outcomes of persons with
CF born during 1973–1981 in Veneto and Trentino and de-
tected by newborn screening by meconium albumin testing
with persons with CF diagnosed conventionally in Veneto and
Trentino and two neighboring regions without screening (88)
(Table 3). A second analysis compared outcome data on chil-
dren with CF born during 1983–1992 in Veneto, where screen-
ing with CF was universal, with data on children with CF
born in Sicily, where CF newborn screening was not practiced
(88) (Table 3). Although the investigators reported that the
two groups had similar frequencies of severe CFTR mutations
and comparable treatment protocols, the two regions differ in
socioeconomic status (89). Another analysis by other investi-
gators compared persons with CF born during 1973–1992
who were examined at the CF center in Verona, distinguish-
ing between those who received a diagnosis by newborn screen-
ing and those who received a diagnosis clinically (90).
Cohort studies have at least two limitations that decrease
their usefulness as evidence for a causal effect of newborn
screening for CF. First, historic controls, as used in both the
Australian and Dutch studies, are subject to bias because of
improvements in CF treatment over time (89). In the case of
the Australian study, such changes might overstate the appar-
ent benefits of screening, whereas in the Dutch analysis, the
effect would be in the opposite direction. Second, concurrent
controls from different regions are subject to bias from varia-
tion in the quality of CF care provided across regions (89).
Registry Studies
Population-based CF registries in the United States and the
United Kingdom have been used to model the effect of new-
born screening on outcomes. The United Kingdom Cystic
Fibrosis Database (UKCFD) was established in 1995 and in-
cludes data from 41 large specialist CF centers and 12 smaller
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CF clinics (91). One analysis of the UKCFD data compared
outcomes for two groups of children aged 1–9 years, exclud-
ing those with meconium ileus: children who received a diag-
nosis on the basis of newborn screening before age 3 months
(n = 184) and children who received a diagnosis on the basis
of symptoms, excluding those with a positive family history
(n = 950) (91).
In the United States, the CFF National Patient Registry
(CFNPR) contains information on >23,000 persons with CF
cared for through a national network of CFF-accredited CF
care centers and affiliated satellite clinics. These centers and
their affiliates provide integrated, multidisciplinary care and
have collaborated to develop standardized data-collection pro-
tocols (34). CFNPR data are made available by CFF to re-
searchers and have been used in numerous statistical studies
of outcomes.
Registry data have at least three limitations. First, how per-
sons were detected might be misclassified. For example, among
27,703 persons who appeared in CFNPR >1 time during
1986–2000, a total of 69 (8%) of 898 persons who report-
edly received a diagnosis on the basis of newborn or prenatal
screening did not receive their diagnosis until age >12 months
(92), and 90 (10%) received a diagnosis before 1980 (93)
even though screening was first introduced in the United States
in 1982. Second, because persons detected by screening are
more likely to have been born more recently and CF out-
comes have improved over time, comparison of screened and
unscreened groups that do not control for year of birth are
subject to bias. Differences in race/ethnicity, genotype, pan-
creatic insufficiency, and birth year can be controlled in sta-
tistical analysis. Also, because newborn screening is closely
correlated with region of birth, regional differences in quality
of care might be difficult to separate from screening as an
influence on CF outcomes. Finally, registry data, like all ob-
servational data, are subject to ascertainment bias (89). This
is particularly a problem for studies that set a low cutoff for
age of diagnosis (e.g., age 36 months). In the absence of screen-
ing, age at diagnosis varies substantially, and a person with
milder clinical symptoms is more likely to receive a diagnosis
at a later age.
Disease-Oriented Outcomes
Nutritional Outcomes
The most convincing evidence of health outcomes from
screening for CF is in the area of nutrition and growth
(19,89,94). In the absence of early treatment, infants and chil-
dren with CF are subject to growth failure and prolonged vi-
tamin deficiency. Anthropometric measures of nutritional
status include height and weight, weight relative to height,
and, for infants and young children, head circumference. The
majority of studies have compared heights and weights to ref-
erence growth curves by using Z-scores, with a 1.0 difference
in Z-score roughly corresponding to a difference of 1 SD in
the reference curve (95). The absolute difference in weight or
height for a given Z-score varies by age.
In 1997, the Wisconsin Cystic Fibrosis Neonatal Screening
Project demonstrated that diagnosis resulting from newborn
screening and early intervention was associated with better
growth (28). A subsequent analysis that included growth
measurements before age 4 years for children in the control
group unblinded at that age and with more years of follow-up
provided conclusive findings (77) (Table 4). When pooled
across all ages with a statistical model that controlled for
covariates and interaction terms, children in the screened co-
hort were substantially taller (p<0.01) and slightly heavier (p
= 0.06) than children in the standard diagnosis (control) co-
hort (62). Visual inspection of the graphs reveals that differ-
ences in mean height-for-age persisted through age 10 years
but that the difference in weight-for-age disappeared after age
4 years (62). No differences in weight-for-height were observed
at any age. The magnitude of the difference in height-for-age
Z-scores varied among children aged 4–10 years (range: 0.2–
0.5) (62). The U.K. RCT did not report substantial differ-
ences in either weight or height through age 4 years; however,
<20 children were followed for 4 years (78). The difference in
findings might also reflect differences in follow-up care, which
was not standardized in the U.K. study.
Decreased risk of chronic malnutrition or growth retarda-
tion, typically defined as being below the 5th or 10th percen-
tiles for height or length relative to age, might be more
important from a clinical perspective than mean height-for-
age, because it is associated with increased risk of childhood
morbidity and death (96–98). The percentages of children in
the Wisconsin RCT being below the 10th percentiles for
height-for-age and weight-for-age were substantially lower in
the screened group, adjusting for covariates (e.g., age and geno-
type) (p<0.01) (77). In the control group, the percentage with
low height-for-age declined from 40% at age 1 year to ap-
proximately 20% by age 4 years and remained stable, whereas
the percentage in the screened group with low height-for-age
was approximately 10%–15% through age 8 years. Among
infants and young children, growth retardation without a
known cause is referred to as failure to thrive. Failure to thrive
is one of the leading developmental disorders among young
children (97), as well as a common cause of pediatric hospi-
talization (98), and prevention of failure to thrive can reduce
health-care costs and avert parental anxiety.
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TABLE 4. Summary of evidence on health benefits from newborn screening for cystic fibrosis (CF) comparing screened and
unscreened groups measured at same ages
Growth and Bacterial Pulmonary Cognitive
Location nutrition colonization Lung function scores Survival function Care use
Randomized controlled trial
Significant
differences in
height Z-score
and percentage
low height and
weight in favor of
screened group*
(p<0.01)
Wisconsin Shorter time to
infection for
screened
children seen at
one center but
not overall†
At age 7 years,
12% of
screened, 25%
of controls <90%
forced expiratory
volume in 1
second (FEV1)
n.s.§¶**
Chest
radiograph
scores
significantly
worse at age 12
years in
screened group,
but no significant
difference after
controlling for
infections**
Insignificant
difference of 5
points on
Cognitive Skills
Index; for subset
with vitamin E
deficiency,
significant
difference of
12.5 points††
(p<0.05)
Hospital use by
51% in screened
group and 34%
of control group;
no control for
confounding by
genotype or
infections§§
Wales and West
Midlands
No significant
difference in
weight or
height¶¶
No difference at
ages 1–4
years¶¶
Four CF-related
deaths in 71
unscreened
children versus
0/71 among
screened cohort
(p<0.05)***
Screened cohort
spent 19.2 days
in hospital in first
year of life
versus 27.0 days
for unscreened
children
(p<0.01)¶¶
Cohort study
Australia Difference in
height in favor of
screened group
significant at
ages 1 and 5
years†††
Significant
difference in
FEV1 in favor of
screened group
at ages 5, 10,
and 15 years
(p<0.01)†††§§§
Significant
difference in
chest
radiographs in
favor of
screened group
at age 15 years
(p<0.05)§§§
Death rate 47%
lower among
screened cohort,
n.s.¶¶¶
Screened cohort
spent 4 days in
hospital during
first 2 years of
life versus 27
days for
unscreened
cohort¶¶¶
France Differences in
height Z-scores
of 0.3–0.6 in
favor of
screened group
significant at
ages 1, 3, and 5
years
(p<0.05)****
No difference**** No difference**** Better chest
radiograph and
clinical scores for
screened
children
(p<0.05)****
3 CF-related
deaths in 36
unscreened
children versus
0/77 in screened
cohort
(p<0.05)****
Hospitalizations
among 49% of
screened and
86% of
unscreened
cohort
(p<0.0001)****
Italy —
geographic
controls (Sicily)
Differences in
height in favor of
screened group
significant at
ages 0–2 years
through ages
14–16 years
(p<0.01)††††
18 deaths in 152
unscreened
children versus
2/126 in
screened cohort
(p<0.001)††††
Italy — within-
region controls
Differences in
height in favor of
screened group
significant at
ages 6–8 years
through ages
14–16 years
(p<0.01)††††
No difference in
mortality at age
<10 years††††§§§§
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TABLE 4. (Continued) Summary of evidence on health benefits from newborn screening for cystic fibrosis (CF) comparing
screened and unscreened groups measured at same ages
Growth and Bacterial Pulmonary Cognitive
Location nutrition colonization Lung function scores Survival function Care use
Cohort study
Netherlands —
contemporaneous
controls
Height Z-score
greater by 0.42
for screened
group, n.s.¶¶¶¶
Higher scores in
screened group,
n.s.¶¶¶¶
Adjusted relative
risk of dying 57%
lower for
screened group,
n.s.¶¶¶¶*****
Netherlands
Post–screening
controls
Height Z-score
lower by 0.17 in
screened group,
n.s.¶¶¶¶
No difference¶¶¶¶ Adjusted relative
risk of dying 65%
lower for
screened group,
n.s.¶¶¶¶
Registry
United Kingdom
Cystic Fibrosis
Database
Height Z-score
higher by 0.32 in
screened group
than in clinical
diagnosis group
(p<0.005);
controlling for
genotype 0.22,
n.s.†††††
Lower rates in
screened group
than in clinical
diagnosis group
at ages 1–3
years (p<0.005)
†††††
No difference Better chest
radiograph and
clinical scores at
ages 1–3 years
and ages 7–9
years
(p<0.05)†††††
~20% lower use
of high-cost
therapies in
screened group
than in clinical
diagnosis group
at ages 1–3
years and ages
4–6 years
(p<0.05)†††††
United States
Cystic Fibrosis
Foundation
National Patient
Registry
No difference§§§§§ No difference§§§§§ No difference
among those
receiving
diagnosis after
1986§§§§§¶¶¶¶¶
* Source: Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves
long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001;107:1–13.
† Source: Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young
children with cystic fibrosis. Pediatr Pulmonol 1998;26:81–8.
§ Not significant
¶ Source: Farrell PM, Li Z, Kosorok MR, et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol
2003;36:230–40.
** Source: Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit
Care Med 2003;168:1100–8.
†† Source: Koscik RL, Farrell PM, Kosorok MR, et al. Cognitive function of children with cystic fibrosis: deleterious effect of early malnutrition. Pediatrics
2004;113.
§§ Source: Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr (suppl) (in press).
¶¶ Source: Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years
of screening. Arch Dis Child 1991;66:29–33.
*** Source: Doull IJ, Ryley HC, Weller P, Goodchild MC. Cystic fibrosis-related deaths in infancy and the effect of newborn screening. Pediatr Pulmonol
2001;31:363–6.
††† Source: Waters DL, Wilcken B, Irwing L, et al. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80:F1–7.
§§§ Source: McKay KO, Waters DL, Gaskin KJ. The influence of newborn screening for cystic fibrosis on pulmonary outcomes in New South Wales. J Pediatr
(suppl) (in press).
¶¶¶ Source: Wilcken B, Chalmers G. Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 1985;2(8468):1319–21.
**** Source: Siret D, Bretaudeau G, Branger B, et al. Comparing the clinical evolution of cystic fibrosis screened neonatally to that of cystic fibrosis diagnosed
from clinical symptoms: a 10-year retrospective study in a French region (Brittany). Pediatr Pulmonol 2003;35:342–9.
†††† Source: Mastella G, Zanolla L, Castellani C, et al. Neonatal screening for cystic fibrosis: long-term clinical balance. Pancreatology 2001;1:531–7.
§§§§ Source: Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of
intense neonatal screening over 30 years. Am J Epidemiol 2002;156:397–401.
¶¶¶¶ Source: Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical
outcome and survival of CF patients. Eur Respir J 2001;18:306–15.
***** Not statistically significant.
†††††Source: Sims EJ, McCormick J, Mehta G, Mehta A. Neonatal screening for cystic fibrosis is beneficial even in the context of modern treatment. J Pediatr
(suppl) (in press).
§§§§§Source: Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in
patients with cystic fibrosis. Am J Epidemiol 2004;159:537–46.
¶¶¶¶¶ Source: Lai HJ, Cheng Y, Farrell PM. The survival advantage of cystic fibrosis patients diagnosed through neonatal screening: evidence from the U.S.
Cystic Fibrosis Foundation Registry data. J Pediatr (suppl) (in press).
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** The Australian cross-sectional analysis identified significant differences in
height-for-age (p<0.05) but not in weight-for-age; a longitudinal analysis
of a subset of observations identified significant differences in weight-for-
age (p<0.05) but not in height-for-age (81).
As was true of the Wisconsin RCT, observational studies
have reported greater height-for-age and, to a lesser extent,
weight-for-age among children detected through screening.
In Australia, repeated analysis of cross-sectional differences
indicated that mean height-for-age Z-score was consistently
greater by 0.4 among a cohort of 60 children born after screen-
ing was started in 1981 compared with a cohort of 57 chil-
dren born during the 3 previous years. However, as a result of
attrition, the differences were statistically significant only at
age 1 year and age 5 years (p<0.05) (81).** At age 15 years,
the mean difference in height was 3.4 cm (95% confidence
interval [CI] = –0.4–7.2) and the mean difference in height-
for-age Z-scores was 0.4 (95% CI = –0.1–0.9) (82). Data from
the Dutch screening pilot study indicated a similar differen-
tial in height-for-age, with a difference in predicted height
through age 12 among 18 children with CF in the screened
group of 0.42 SD (95% CI = –0.20–1.04) compared with 24
unscreened children born during the same period; owing to
the limited number of observations, this difference was not
statistically significant (85). Compared with children born after
screening, heights and weights were slightly but not substan-
tially lower in the screened group, which could reflect better
nutritional therapies available to the more recent birth co-
horts (85). In France, children born in Brittany (where new-
born screening has been in practice since the 1980s) had higher
average height and weight Z-scores than those born in neigh-
boring Loire-Atlantique (where screening was not in practice).
Differences in height-for-age Z-scores, which were primarily
0.3–0.6 at each age, were statistically significant at ages 1, 3,
and 5 years, and differences in weight-for-age were statisti-
cally significant at ages 1 and 8 years (p<0.05) (87).
An analysis of UKCFD cross-sectional data for 2002 deter-
mined an overall difference in median height-for-age Z-score
of 0.32 among U.K. children with CF detected through new-
born screening compared with those detected on the basis of
clinical symptoms (p<0.005) (91). By 3-year age groups, dif-
ferences in height Z-scores were 0.39 at ages 1–3 years and
0.32 at ages 4–6 years (p<0.05), whereas a Z-score difference
of 0.27 among those aged 7–9 years was not statistically sig-
nificant. For the subset of children homozygous for the ∆F508
mutation, the difference in height-for-age Z-score was smaller
(0.22; 95% CI = –0.01–0.44) and did not reach statistical
significance. The difference in median weight-for-age Z-scores
was smaller and not statistically significant in either analysis.
In Italy, two analyses determined evidence of nutritional
advantage from screening. First, a study conducted among
children born in northeastern Italy during 1973–1981, when
a pilot screening of meconium albumin was in place, revealed
that those detected by screening, all with pancreatic insuffi-
ciency, had weight Z-scores better than the non–meconium
ileus symptomatic group with pancreatic insufficiency at ages
4–6 years through ages 16–18 years (p<0.05); height Z-scores
were significantly different from ages 6–8 years through ages
14–16 years (range: 0.6–1.0; p<0.05) (88). A second analysis
compared all children born in Veneto during 1983–1992,
when IRT screening was in place, with those born in Sicily,
which had an intensive program of promoting early diagnosis
on the basis of symptoms. Differences in height Z-scores were
statistically significant at each 2-year age group from ages 0–2
years through ages 14–16 years (range: 0.4–0.8; p<0.01,
except for ages 2–4 years) (88).
Another nutritional benefit of newborn screening is earlier
initiation of vitamin supplements. Deficiencies of fat-soluble
vitamins (vitamins A, E, and K) are common among children
with CF not receiving nutritional supplements (99); for ex-
ample, half of infants in the Wisconsin RCT had vitamin E
deficiency at diagnosis (77,100). Prolonged vitamin E defi-
ciency can in certain cases lead to hemolytic anemia and other
adverse outcomes, which can potentially be avoided through
early diagnosis and intervention. These deficiencies can be
corrected by nutritional therapy, and few children in either
group in the Wisconsin trial had vitamin deficiencies when
assessed later (77). An analysis of cognitive scores supported
the hypothesis of a developmental effect of prolonged vita-
min E deficiency among children with CF (100).
Pulmonary Outcomes
Existing measures that can be used to quantify early lung
disease in young children with CF are limited. Lung func-
tion, assessed by spirometry, is the most common surrogate
measure of obstructive lung disease and is predictive of sur-
vival in adolescents and adults with CF (101–103). The most
frequently used measure of lung function in CF is forced ex-
piratory volume in 1 second (FEV1) as a percentage of a pre-
dicted value based on height and age, which is usually measured
only among children aged >5 years because of the limited abil-
ity of younger children to cooperate reliably with the testing.
Other pulmonary outcome measures used among children
with CF that might be indicative of the extent of lung disease
are chest radiograph scores (e.g., Brasfield, Wisconsin, and
Northern), which measure structural damage to the lungs,
and Shwachman clinical scores of overall disease severity. Both
types of measures involve subjective assessments. The Wis-
consin study data indicate that chest radiograph scores might
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be a sensitive measure in young children, with half of children
demonstrating signs of potentially irreversible lung damage
by age 2 years (24). Although high-resolution chest tomogra-
phy is an even more sensitive measure of early CF lung dis-
ease, this has not been used as an outcome measure in newborn
screening evaluation studies.
Lung function. Using spirometric measures, the Wiscon-
sin RCT identified no statistically significant difference in lung
function between patients in the screened and standard diag-
nosis groups through age 16 years (29). At age 7 years, 88%
in the screened group and 75% in the control group were in
the normal range (>89% predicted FEV1), and relatively lim-
ited deterioration with age was noted in either group. The
U.K. RCT did not follow children long enough to collect
spirometric measures of lung function.
With one exception, no observational studies have identi-
fied statistically significant differences in lung function asso-
ciated with newborn screening. An Australian study identified
significantly better lung function among patients in the
screened group, including assessments performed at ages 5
(mean difference in predicted FEV1 score: 9.0%; p<0.01), 10
(mean difference in predicted FEV1 score: 9.4%; p<0.05) (81),
and 15 (mean difference in predicted FEV1 score: 12.3%;
p<0.01) years (82). The differential in lung function was great-
est at age 15 years, a mean difference in predicted FEV1 scores
of 12.3% (95% CI = 2.9–21.7). In the Dutch study, the dif-
ferential in FEV1 between the screened group and those who
received a diagnosis conventionally during the same period
(1973–1979) was similar in magnitude, 8.6 (95% CI = –6.0–
23.2) but was not statistically significant. Virtually no differ-
ence was observed in lung function between the screened group
and those who received a diagnosis conventionally in the 6
years after the newborn screening pilot project ended (85).
Similarly, in both the French study and the UKCFD analysis,
no differences in lung function were identified between S and
non-S cohorts (87,91). Analyses of CFNPR data likewise have
found no clear evidence of a benefit of newborn screening or
early asymptomatic detection in terms of lung function
(26,93).††
Chest radiograph and clinical scores. Investigators for the
Wisconsin RCT longitudinally analyzed chest radiograph
scores by using two raters for each chest film and two differ-
ent scoring methods to calculate reliable measures of progres-
sion of lung disease (24,29). An analysis indicated that
differences in chest radiograph scores were, if anything, to the
disadvantage of the screened group, except at time of diagno-
sis. Chest radiograph scores measured at the same ages were
similar between the two groups before age 10 years but were
substantially worse in patients in the screened group at age
>12 years (P<0.05) (29). The greater rate of decline in chest
radiograph scores among screened patients occurred only
among those positive for P. aeruginosa. This probably was at-
tributable to a significantly earlier colonization with P. aeruginosa
infection (52 versus 289 weeks) in the screened group followed
at the clinic that in the early years of the study integrated young
and old patients irrespective of their pulmonary status (29).
The U.K. RCT did not find differences in clinical or radiologi-
cal scores between groups at ages 1–4 years (78).
Observational data on lung disease based on subjective ra-
diographic or clinical assessments appear more supportive of
an apparent pulmonary benefit of newborn screening for CF,
but subjective, unblinded assessments could be influenced by
knowledge of the screening status of the child. Three studies
have reported better radiographic outcomes for screened chil-
dren (Table 4). The Australian study reported significantly
better Shwachman chest radiograph scores at age 15 years
among patients in the screened group (2.3; 95% CI = 0.3–
4.2), although not at ages 5 or 10 years; the difference in
Shwachman clinical scores was statistically significant at ages
5 (3.8; p<0.01), 10 (5.3; p<0.05), and 12 (7.0; p<0.05) years
(81,82). In France, both Brasfield chest radiograph scores and
Shwachman clinical scores were significantly better among
screened children (p<0.05) at each age; Brasfield scores among
screened children declined 8% as children aged 1–9 years,
compared with a 20% decline among unscreened children
(87). Lastly, an analysis of UKCFD data has reported signifi-
cantly better Northern chest radiograph scores (1.0; 95% CI
= 0.0–0.99) and Shwachman clinical scores (3.0, 95% CI =
1.0–4.0) in neonatally screened patients ages 1–9 years
(p<0.05) (91). Significant differences of comparable magni-
tude were apparent when the analysis was restricted to ∆F508
homozygotes to control for potential confounding by geno-
typic differences.
Respiratory microbiology. In principle, newborn screen-
ing can allow for interventions to delay the onset of chronic P.
aeruginosa colonization. A study from Denmark has reported
that frequent culturing of specimens from persons with CF
and aggressive treatment of first infections with P. aeruginosa
avoids or delays the onset of chronic colonization (31). An
analysis of UKCFD data has reported lower rates of both tran-
sient and chronic P. aeruginosa infection among young chil-
dren detected by newborn screening (91). Among children
aged 1–3 years, only half as many children in the screened
group had at least one positive P. aeruginosa culture, both over-
†† One study reported a possible association of early asymptomatic detection
and lung function among a subset of children born during 1987–1990, but
ascertainment bias was a problem, because only children who received a
diagnosis by the end of 1990 were included (26).
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all and among ∆F508 homozygotes (p<0.01); among ∆F508
homozygotes, a significantly lower proportion of children had
three or more positive cultures (p<0.05) (91). In the United
Kingdom, at least one CF center that participates in newborn
screening also provides aggressive interventions against P.
aeruginosa infections (43); the statistical finding could possi-
bly reflect an association of newborn screening with varia-
tions in CF care. However, among children aged >3 years,
which would include children with milder CF diagnosed symp-
tomatically at later ages, no difference in rates of positive cul-
tures was observed (91).
Studies from France and the United States have not reported
lower rates of isolation of P. aeruginosa from respiratory cul-
tures taken from screened children with CF, including the
Wisconsin RCT (76,87). An analysis of CFNPR data reported
that although children with early asymptomatic detection had
a lower frequency of colonization with this pathogen overall,
after state of birth and other variables were controlled for,
these children did not have a lower risk (104). Similarly, an
analysis of CFNPR data reported that risk of earlier acquisi-
tion of P. aeruginosa among children detected symptomati-
cally did not differ significantly from those detected by
screening after controlling for confounding variables (e.g.,
genotype) (93). An analysis of CFNPR data from 2000–2002
determined that 15% of infants with CF detected by new-
born screening had positive cultures for P. aeruginosa, com-
pared with 25%–29% among infants detected on the basis of
symptoms, but fewer than half of persons with CF detected
by symptoms received a diagnosis as infants (27).
Patient-Oriented Outcomes
Survival
Because of low CF mortality rates in childhood, a substan-
tial number of subjects would be required to detect statisti-
cally significant differences in survival between screened and
unscreened cohorts (5). Also, including deaths unrelated to
CF and deaths among children with meconium ileus might
mask benefits in terms of preventable CF-related deaths.
Data from the the U.K. RCT supplemented by ascertain-
ment of CF-releated deaths from the UKCFD and other
sources indicate that significantly fewer CF-related deaths
occurred among the screened cohort (79); four CF-related
deaths were recorded before age 5 years among 71 children
who were selected randomly not to be screened, and no early
CF-related deaths were reported among 78 children selected
randomly to be screened (p<0.05). However, two of the four
deaths occurred among children who received a diagnosis by
age 7 weeks and might not have been preventable by screen-
ing. The other two deaths occurred among children who did
not receive a diagnosis before death, which highlights preven-
tion of undiagnosed CF mortality as a potential benefit of
screening (86). Whether undiagnosed CF mortality is wide-
spread in the United States is not known. Wisconsin study
investigators examined death records for children who were born
during the study period (62) but determined that no children
had died with CF before receiving a diagnosis (Philip M.
Farrell, M.D., Ph.D., University of Wisconsin Medical School,
Madison, personal communication, November 20, 2003). No
survival data from the Wisconsin RCT have been published.
Observational studies have consistently identified lower
mortality rates in screened relative to unscreened cohorts. Stud-
ies in Australia (82) and the Netherlands (85) used an intent-
to-treat approach. In the Australian study, CF-related mortality
among children aged <15 years was 47% lower among the
screened cohort (6.7%) than among those born before screen-
ing (12.7%); this difference is not statistically significant, al-
though deaths among the screened cohort occurred an average
of 4 years later (p<0.05) (82). In the Dutch study, the relative
risk for dying through age 12–24 years for 24 persons in the
screened group was 0.43 (95% CI = 0.13–1.38) compared
with 29 persons in the unscreened group born during the same
period and 0.35 (95% CI = 0.09–1.41) compared with 34
persons with CF born after screening was terminated (85).
Even greater relative differences in survival within 6–12 years
after birth were apparent, but no separate statistical analysis
was reported.
Two observational studies from Europe have reported sta-
tistically significant differences in CF mortality comparing
regions with and without newborn screening for CF. An analy-
sis of Italian data that compared mortality among 126 chil-
dren with CF born during 1983–1992 in the northeast in
Veneto, which screened for CF, with mortality among 152
children born in the south in Sicily, which did not screen for
CF, indicated that two deaths occurred among the former
population and 18 among the latter (88). However, two analy-
ses of data from Veneto and neighboring regions in Italy did
not find mortality before age 10 years to be substantially lower
among children with CF detected by screening (88,90). A
similar analysis in France did not follow an intent-to-treat
analysis but compared children detected by screening with-
out meconium ileus born in two regions with those who re-
ceived a diagnosis on the basis of symptoms other than
meconium ileus. Three CF-related deaths occurred among 36
children born in Loire-Atlantique during 1989–1998 who were
detected on the basis of symptoms other than meconium il-
eus, and none occurred among 77 children without meco-
nium ileus in neighboring Brittany who were detected through
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screening, a statistically significant difference (p<0.05) (87).§§
Both studies reported similar prevalence of CF and similar
CF treatment protocols across regions (87,88).
In the United States, analysis of CFNPR data during 1986–
2000 identified a higher risk for death among persons with
CF detected by symptoms rather than by screening (p<0.05)
(92,93). However, this finding was based on less reliable data
on diagnosis type from births occurring during the period
before screening was widely available; no significant differ-
ence in survival between those detected through screening and
those detected by symptoms other than meconium ileus was
identified among those who received a diagnosis after 1986
(92,93).The survival curves were almost identical between the
screened and symptomatic-detection post-1986 diagnosis
groups through age 14 years. The analysis does not provide
evidence of improved child survival through screening.
Because newborn screening has been demonstrated to pre-
dict nutritional status, an indirect assessment of the effect of
screening on survival can be derived from observational stud-
ies of the association of nutritional status with survival among
children with CF (101). One multivariate analysis of CFNPR
data determined that children with weight-for-age less than
the fifth percentile between ages 1–5 years were four times
more likely to die over the ensuing 8 years than patients with
weight-for-age >50th percentile (95% CI = 2.1–7.3) (105).
Height-for-age, the outcome most consistently associated with
newborn screening in the Wisconsin trial as well as observa-
tional studies, has also been linked with mortality risk in CF.
One analysis of CFNPR data during 1980–1993 indicated
that male children aged 7 years with height-for-age below the
fifth percentile had an unadjusted relative risk of dying dur-
ing childhood and adolescence of 6.3 (95% CI = 2.1–16.7)
(96). A multivariate analysis of adolescents and adults with
CF in England also determined that height was strongly pre-
dictive of subsequent mortality (p<0.0001) (102).
Cognitive Function
The 1997 workshop recommended that data be collected
to analyze cognitive outcomes among children with CF clas-
sified by age of detection to determine whether advantages in
early growth might have lasting neurodevelopmental conse-
quences (5). To this end, cognitive assessments were performed
at ages 7–17 years on 89 children in the Wisconsin study for
whom consent could be obtained, including 67 children with-
out meconium ileus and with no missing data (100). Cogni-
tive function was assessed with the Test of Cognitive Skills,
2nd Edition, which was used to generate the Cognitive Skills
Index (CSI) (mean = 100; SD = 16), a validated measure of
general intelligence equivalent to an IQ (106). Overall, the
screened group had a 5-point higher mean CSI score relative
to the control group, which is equivalent to one third SD,
controlling for confounding variables. This finding was not
statistically significant. No association was identified with any
anthropometric indicator, including head circumference,
height, and weight (100).
A larger and statistically significant CSI differential was
observed among the approximately 50% of children in the
Wisconsin RCT who had vitamin E deficiency at time of di-
agnosis (100). The 17 control group subjects who had low
alpha-tocopherol levels at time of diagnosis had adjusted CSI
scores 12.5 points lower than scores for the 17 screened sub-
jects who also had vitamin E deficiency at diagnosis (p<0.05).
Differences in cognitive ability of this magnitude are percep-
tible to patients; a reduction of 1 SD in cognitive scores is
associated with a decrement in reported HRQoL (107).
Health-Related Quality of Life
 Health-related quality of life (HRQoL) is a common mea-
sure for studies of clinical utility. The 1997 workshop recom-
mended that HRQoL among children and adolescents with
CF be assessed to determine whether early intervention re-
sulting from newborn screening leads to better outcomes from
the person’s own perspective (5). HRQoL can be assessed by
using either generic instruments or disease-specific instru-
ments; the majority of studies of HRQoL have used generic
instruments (e.g., the Quality of Well-Being [QWB] Scale or
Child Health Questionnaire [CHQ]). Studies that used ge-
neric HRQoL instruments with persons with CF have reported
that HRQoL is negatively associated with recent morbidity
(e.g., number of respiratory infections, concurrent medical
conditions, and daily medications) but appears to be unre-
lated to nutritional status or lung function (108,109).
In response to the 1997 workshop recommendation, a
follow-up study of HRQoL was conducted among a subset of
89 participants in the Wisconsin RCT assessed at ages 7–17
years. Results using the CHQ indicate that HRQoL did not
differ between the screened and control groups (107). The
best predictor of lower HRQoL in one of the regression mod-
els was the number of recent hospitalizations, consistent with
previous studies (108,109). Because the generic HRQoL in-
strument used in this study is reported to have limited sensi-
tivity compared with disease-specific instruments for CF in
measuring differences in health states (110), a more sensitive
disease-specific instrument might have revealed between-group
differences in HRQoL.
§§ Four deaths not related to CF were recorded among screened children with
CF in Brittany, three of which occurred neonatally. Infants with CF who
died from such causes would not have received a diagnosis of CF in the
absence of screening. In addition, one child with CF in Brittany died from
causes associated with Down syndrome (87).
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Another limitation of the HRQoL study is that it was con-
ducted long after diagnosis among respondents of different
ages. More research on HRQoL among younger children with
CF is warranted to assess the potential qualitative benefits of
newborn screening. Cross-sectional assessments of HRQoL
among children who already have received a diagnosis of CF
cannot capture adverse effects on quality of life occurring
during the period before diagnosis. For example, enteric-coated
pancreatic enzyme therapy has been demonstrated to reduce
the frequency of abdominal pain among older children, ado-
lescents, and adults (111). By allowing for earlier initiation of
enzyme therapy, newborn screening could lead to improve-
ments in HRQoL among the subset of infants with gastrointes-
tinal symptoms during the interval before initiation of therapy
prompted by symptomatic diagnosis.
Hospitalizations and Burden of Care
As noted previously, studies among persons with CF have
indicated that severe symptoms requiring multiple medica-
tions and hospitalizations are associated with statistically sig-
nificant decrements in HRQoL (107,108,110). Because
hospitalizations and prescription medications comprise the
bulk of medical costs for persons with CF (112), any inter-
vention that leads to reduced hospitalizations and concurrent
pharmacologic treatments can substantially reduce costs to
the health-care system and improve the well-being of affected
children and their families.
Evidence relating newborn screening to the cost and burden
of hospitalizations or medications is suggestive of benefit for
these patient-oriented outcomes. The U.K. RCT data indicate
that children in the screened cohort spent a statistically signifi-
cantly shorter amount of time in the hospital during the first
year of life than those in the unscreened cohort (mean [SD] =
19.2 [42.9] and 27.0 [22.7] days, respectively) (p<0.01).
The Wisconsin RCT has not confirmed a reduction in hos-
pitalizations; 51% of persons in the screened group had a re-
corded hospitalization at any age, compared with 34% of the
control group (69). The hospitalization rate for the unscreened
group in Wisconsin was lower than expected and might re-
flect underascertainment of data on hospitalizations. An ear-
lier analysis reported higher rates of hospitalization within the
screened group controlling for CF center, although the differ-
ences were not statistically significant (76).
Four observational studies have reported that diagnosis re-
sulting from newborn screening is associated with fewer hos-
pitalizations among young children with CF. In Australia, the
average number of hospital days in the first 2 years of life was
27 for the unscreened cohort and 4 for the screened cohort
(80). In France, the cumulative frequency of hospitalizations
for children with CF is reported to have been significantly
lower in a screened cohort than in a neighboring unscreened
cohort (49% and 86%, respectively; p<0.001) (87). An analysis
of CFNPR data from 2000–2002 on infants aged <12 months
who received a diagnosis of CF reported that 22% of infants
who received a diagnosis through newborn screening were hos-
pitalized during the year of diagnosis, compared with 64% of
infants who received a diagnosis on the basis of clinical symp-
toms (27). An earlier study from Colorado (113) reported an
even larger differential, but that analysis was restricted to hos-
pitalizations occurring before diagnosis, which is less
meaningful.
According to one study (114), antibiotic prophylaxis against
infections with Staphylococcus aureus reduced hospitalizations
among young children with CF detected through newborn
screening, but conclusive evidence is lacking. One RCT con-
ducted in East Anglia during 1985–1989 randomly selected
38 infants identified with CF through newborn screening to
receive either continuous antibiotic prophylaxis with
flucloxacillin or episodic treatment (114). During the second
year of life, mean hospitalization admission rates in the pro-
phylaxis group were one fourth as high, and mean duration of
hospital stay was one third as high (p<0.01). Two RCTs not
restricted to infants detected by screening (78,115) and using
different antibiotics did not find a preventive effect of pro-
phylaxis (116). One RCT identified an apparent risk of el-
evated P. aeruginosa isolation after 4 years of continual
prophylaxis (115). Certain U.K. centers that use
antistaphyloccocal prophylaxis with aggressive treatment regi-
mens to eradicate P. aeruginosa infections report promising
results in terms of improved outcomes (42,43).
Evidence that early detection by screening might reduce the
number of medications administered, especially more inva-
sive medications, is more limited. In the French study, no dif-
ference between the two cohorts was observed in the frequency
of intravenous antibiotic therapy. However, the screened co-
hort was approximately half as likely to use inhaled antibiot-
ics, a clinically important (albeit not statistically significant)
difference (87). An abstract from a CF care center in
Southampton, England, reported that those receiving a diag-
nosis at age <2 months had statistically significantly lower rates
of using intravenous antibiotics than those who received a
diagnosis at age >2 months (0% and 19%, respectively), regular
nebulized antibiotics (57% and 95%, respectively), and regu-
lar inhaled corticosteroids (36% and 85%, respectively) (all
p<0.05) (117).
UKCFD data indicate a statistically significant lower fre-
quency of use of intensive therapy among children whose CF
was detected by screening compared with those whose CF
was detected by clinical diagnosis (91). Among children aged
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1–3 years, those whose CF was detected through screening
were only half as likely (22% versus 44%) to receive nebu-
lized antibiotics, mucolytics, or corticosteroids. Among chil-
dren aged 4–6 years, the comparable percentages were 41%
and 60%, respectively; p<0.05). By ages 7–9 years, the major-
ity of children in both groups (55% and 67%, respectively)
were receiving such therapies. The lower use of therapies in
the screened group might indicate that a main benefit of screen-
ing is the ability to achieve the same health outcomes with
less burden of treatment on children and families and less cost
to the health-care system (91,117).
Benefits to Families
Children with CF who receive a diagnosis on the basis of
clinical symptoms rather than screening usually experience a
series of diagnostic tests and treatments before a conclusive
diagnosis of CF is made (29). A 1991 Colorado study deter-
mined that 86% of children with CF who were not detected
through screening received an incorrect or incomplete diag-
nosis before a correct diagnosis of CF, and all had undergone
hospitalization (113). On average, 15 months were reported
to have elapsed between the onset of symptoms and a defini-
tive diagnosis of CF. The typical delay from symptoms to di-
agnosis is somewhat shorter, with the median age of diagnosis
for those receiving a diagnosis before age 20 years on the basis
of symptoms reported to be 14.5 months (27).
The adverse effects of delayed diagnosis on families of chil-
dren with CF have been extensively studied (118). Parents of
children detected with CF on the basis of clinical symptoms
are more likely to report experiencing personal distress (119);
anxiety (118); and negative feelings toward, and distrust of,
medical professionals (120,121). In the United States, a syn-
thesis of family experiences with delayed diagnosis includes
anxiety, stress, frustration, self-doubt, and emotional trauma
(29). The possibility of sparing parents the experience of emo-
tional pain as a result of delayed diagnosis might be an impor-
tant benefit of newborn screening. However, receiving a
diagnosis of CF usually causes anxiety, regardless of mode or
age of diagnosis, and parents of children with CF continue to
experience high levels of stress no matter how the diagnosis
was originally established (113,122).
Another potential benefit to parents from a diagnosis of CF
by newborn screening is the ability to make informed deci-
sions related to further childbearing, because the diagnosis
might occur 1 year earlier on average compared with conven-
tional diagnosis (0.5 and 14.5 months, respectively) (27). Six
studies in Europe and Australia indicated that the majority of
couples with positive CF newborn screening results use that
information in their childbearing decisions (123). Limited
evidence from two U.S. studies suggests less reproductive ef-
fect of newborn screening (113,124), which might reflect dif-
ferences in genetic counseling or cultural attitudes (125).
Evidence for Risks of Harm
Potential harms from newborn screening can occur both to
children with CF and their families and to families of chil-
dren who have a false-positive newborn screen. On the basis
of previous experience with genetic screening programs
(1,126,127), certain psychosocial risks were anticipated, no-
tably parental anxiety and disturbance of the parent-child
bond. These risks are related to the communication process
and the experience of families being informed about screen-
ing results (14). Appropriate resources for diagnostic evalua-
tions, treatment for infants with CF, and counseling for families
might help mitigate these risks (128–130). Ongoing quality-
assurance programs built into the screening system are needed
to provide accurate data on risks.
Risks to Infants Affected with CF
and Their Families
Altered Parent-Child Relationships
Before the introduction of newborn screening for CF, the
possibility that screening could have an adverse effect on the
bonding process between new parents and their infants had
been hypothesized (127). Studies of families of children with
CF have investigated the hypothesis, and none has determined
this to be a problem. For example, a study of 58 families of
Australian children with CF, half of whom were detected
through newborn screening, did not find evidence of altered
maternal behavior in response to a diagnosis of CF through
newborn screening (119). A study from Wales in 1999 of nine
mothers of children with CF detected through newborn screen-
ing and 82 mothers from the general population identified
no evidence of greater rejection or overprotection in the CF
group (131). Although the number of families studied is lim-
ited, these reports suggest that early identification of CF
through newborn screening does not adversely alter parent-
child relationships.
Person-to-Person Transmission
of Infectious Agents
The Wisconsin RCT documented earlier acquisition of P.
aeruginosa among infants detected through screening who were
examined at a CF center housed in a 90-year-old building
with a 110-square-foot waiting room in which screened in-
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fants were not isolated from older children with CF, many of
whom had lung infections (28,30).¶¶
Children in the screened group who were examined at the
first center acquired P. aeruginosa at a median age of 1.0 years,
compared with a median of 5.6 years for those examined at
the other center (76). Evidence from Australia documenting
acquisition of P. aeruginosa from other persons with CF cared
for at the same center supports the hypothesis that this is a
concern in the treatment of infants and young children with
CF (132). Centers caring for children with CF should address
this problem, whether CF is detected clinically or through
newborn screening.
The Wisconsin evidence indicates that person-to-person
transmission of P. aeruginosa is not an inherent risk of new-
born screening and can be avoided. It does not appear to be
common among children with CF detected by newborn screen-
ing in the United States (27). A study of 180 children in Colo-
rado detected by newborn screening identified a median age
of acquisition of P. aeruginosa of 8.1 years (133). In 2003,
CFF issued new recommendations to minimize the risk of
person-to-person transmission of infectious agents, including
segregating asymptomatic patients from those with established
disease (134). Studies to evaluate the efficacy and use of
infection-control policies should be conducted.
Risks to Infants with False-Positive CF
Screens and Their Families
The anticipation of psychosocial risks to parents whose in-
fants have a false-positive CF screening result was based on
previous experiences with newborn screening for PKU (135)
and with other benign conditions (e.g., hyperbilirubinemia
and heart murmurs) that resulted in anxiety and
overprotectiveness among certain families (136). With a simple
IRT/DNA approach, all children with positive screens either
have CF or are CF carriers (62), although this is not the case
in programs that also refer children with highly elevated IRT
and no detected mutations.
Psychological Distress from Screening
Parents of children who screen positive for CF, the majority
of whom do not have CF, often report feeling distress and
anxiety. One study from Wisconsin of 104 parents whose in-
fants had elevated IRT measures indicated that parents sur-
veyed while waiting for results of sweat tests reported feelings
of concern (96%), depression (77%), and shock (76%) (120).
A minority of families of children with false-positive screen
results reported lingering anxiety even after being informed
that their child did not have CF. A study in Wisconsin of 106
parents whose infant had positive screens under the IRT screen-
ing algorithm and 63 parents whose infants screened positive
under the IRT/DNA (single-mutation) algorithm (none of
whom had CF) determined that, when interviewed 1 year af-
ter screening, 7% and 10%, respectively, reported that they
worried about the results once a week or more (124).
Misunderstanding of Carrier Status
The information that a child with a positive screen is a car-
rier, that at least one of the parents is a carrier, and that the
parents are at increased risk of having a child with CF, is com-
plex to convey. A Wisconsin study of 63 families with positive
IRT/DNA test results reported that 6% of families thought
that being a carrier could cause illness (124). Education and
genetic counseling might improve understanding, but a sec-
ond study from Wisconsin of 138 families conducted after
CF screening had become part of the state newborn screening
program indicated that only two thirds of parents received
genetic counseling (i.e., counseling from a physician, nurse,
or genetic counselor) (137). In this cohort, 88% understood
that their child was a carrier, but not all had accurate under-
standing of the implications; 11% either believed that their
child would have CF subsequently or did not know whether
that could happen (137). Approximately half of parents re-
ported feeling confused, and only one fourth of families re-
ported feeling no anxiety about their child’s carrier status. Less
than half of the parents, regardless of whether they reported
receiving genetic counseling, understood that they were at
increased risk of having a child with CF. These findings un-
derscore the need for comprehensive communication plans,
research about effective risk-communication strategies, and
assessments of parental understanding of routine screening
programs (128).
Other Implications to Families of Carrier
Identification
The provision of information about CF carrier status has
raised concerns about potential stigmatization and discrimi-
nation (138), although subsequent studies have not yielded
evidence of such adverse effects. In addition, certain persons
have reported feeling uncomfortable with the implications of
contacting other family members about CF carrier status (131).
States screening newborns for SCD*** have long experience
in reporting sickle cell trait, which poses similar challenges in
communicating complex genetic information to families (139).
*** As of August 2004, all but two states routinely screened newborns for
hemoglobinopathies (9).
¶¶ Person-to-person transmission of P. aeruginosa in the Wisconsin study was
not documented through microbiologic analysis.
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Despite these concerns, studies indicate that the majority
of parents of carriers detected by screening consider carrier
identification to be a useful by-product of newborn screening
for CF. In Wisconsin, 14% of parents of carriers in one sample
reported that they did not think newborn screening for CF
should be conducted, whereas two thirds of families strongly
agreed that they were better informed by knowing their infant’s
carrier status and would not have preferred that it had re-
mained unknown (137). In Massachusetts, where newborn
screening for CF is optional, preliminary analysis of data on
linked births indicated that 82 of 83 families who had an
infant with a positive screen agreed to newborn screening for
CF for their subsequent infants (140). Also, a study of 10
carrier families in Wales reported that all were in favor of new-
born screening for CF (131). In Massachusetts, one genetic
counseling program reported that 75% of families of infants
identified as carriers requested carrier testing for both par-
ents; among the five families in which both parents were iden-
tified as CF carriers, an older sibling in one family was
subsequently identified as having CF (141).
Risks to Health-Care System
Whenever a condition is added to a newborn screening panel,
potential risks can occur as a result of adding responsibilities
to the health-care system (129). First, infants with false-
negative results might experience a delay in diagnosis. Sec-
ond, overburdening the system with children who are
false-positives could distract primary-care providers and spe-
cialists and complicate addressing the diagnostic and psycho-
social needs of families. These risks can be minimized by
optimizing the screening protocol to minimize false-
negative and false-positive results and by ensuring that ad-
equate resources are available. These two risks emphasize the
importance of collaboration between newborn screening pro-
grams and health-care providers in planning and implement-
ing a screening program. Finally, screening always has an
opportunity cost, which consists of the diversion of health-
care system resources away from other potential uses.
Failure To Diagnose CF
The American Academy of Pediatrics (AAP) urges health-
care providers to be vigilant to detect disorders included in
newborn screening programs (60,142). This is of particular
importance for CF, because newborn screening for CF results
in more false-negatives than are documented for other estab-
lished newborn screening tests (range of sensitivity in routine
programs: 93%–98%) (Table 2). Providers in states that screen
for CF need to remain vigilant to detect CF among children
with clinical symptoms. In particular, providers should con-
sider the possibility of CF among children with meconium
ileus, children of non-European ancestry who might carry mu-
tations not included in mutation panels used by screening
programs, and children who were born in a state without
screening.
A potential drop in requisitions by primary-care providers
for sweat tests after newborn screening is implemented could
result from physicians not ordering sweat testing on suspicion
of CF even when warranted, thereby risking delayed diagno-
sis, or a reduction in unnecessary ordering of sweat tests with
a low degree of suspicion of CF. In Wisconsin, the number of
sweat tests requisitioned to test for CF is reported to have
decreased 50% statewide after screening was implemented
(68). A reduction of at least one third in the aggregate num-
ber of sweat tests ordered after introduction of newborn screen-
ing for CF has been reported from South Australia (Enzo
Ranieri, M.D., Women’s and Children’s Hospital, Adelaide,
South Australia, personal communication, May 4, 2004).
Another approach to assessing whether changes in provider
behavior might contribute to delayed diagnosis among those
not detected by screening is to compare the median age at
diagnosis among children identified through newborn screen-
ing with those identified through clinical diagnosis in a state
with universal screening. Unpublished data indicate that all
children with CF who have received a clinical diagnosis since
the advent of routine screening in Wisconsin (in 1994) and in
Massachusetts (in 1999) received a diagnosis by age 12 months
(median age at diagnosis: <4 months) (Gary Hoffman,  Wis-
consin State Laboratory of Hygiene, Madison; Anne Marie
Comeau, Ph.D., New England Newborn Screening Program,
Jamaica Plain, Massachusetts, personal communications, April
6, 2004). In Colorado, the median age of diagnosis for 14
children with CF who screened negative is <8 months (Marci
Sontag, Ph.D., The Children’s Hospital, Denver, Colorado,
personal communication, April 8, 2004), which is below the
national average of 14.5 months for diagnoses based on clini-
cal symptoms (27). Thus, no evidence exists that providers
have changed behavior in states with newborn screening for CF.
Effect of False-Positives
The data indicate that the balance between numbers of
screen-positives and cases of diagnosed CF is favorable com-
pared with established newborn screening tests as long as an
IRT/DNA screening algorithm is used (67). An IRT-repeat
IRT protocol can yield similarly low numbers of false-
positives if second specimens are routinely collected from all
infants (18). Screening programs that use an IRT-repeat IRT
protocol with a screen-positive report based on a single speci-
men can expect to generate higher numbers of screen-
positives relative to true-positive cases. Every child who screens
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positive for CF should be referred to a specialty center for a
diagnostic analysis. Health-care providers in Massachusetts
have treated screen-positive results with due diligence, with
>95% of infants with positive screens completing sweat
testing (67).
A concern relating to false-positives is that an increase in
the number of referrals for sweat tests or genetic counseling
could overwhelm CF care centers, thereby adversely affecting
care received by persons with CF. Although CF care centers
will initially need to be prepared to handle a higher volume of
sweat tests, the increase might be modest and transient, de-
pending on the screening algorithm used in a state. One CF
care center in Massachusetts reported a 10% increase in num-
bers of sweat tests requisitioned after the introduction of screen-
ing (Richard B. Parad, M.D., The Children’s Hospital, Boston,
Massachusetts, personal communication, April 15, 2004). The
availability of resources for providing genetic counseling for
families of carriers as well as sweat testing should be addressed
before implementation of newborn screening (140).
Minimizing Risks
All newborn screening tests (including tests for CF) pose
potential risks of harm that need to be minimized through
careful attention to concerns of communicating screening re-
sults and genetic risks and coordination of follow-up among
diagnostic centers, primary-care physicians, genetic counse-
lors, specialists, and families (4,129,143). Screening programs
might minimize psychosocial risks by acting to minimize time
delays between informing parents of positive results and pro-
viding sweat tests; improve the type and nature of informa-
tion given to parents about the meaning of an initial positive
screening result, diagnosis of CF, or identification as a carrier;
and provide psychological support for the families of infants
with CF and for CF carriers who have ongoing concerns (118).
If providers were to educate parents in a relaxed manner
before labor and delivery, a positive screening result might be
met with greater willingness to obtain follow-up and with less
worry about the meaning of a positive test (144,145). New-
born screening information provided to parents at the time
the heel stick is taken, soon after birth in the United States,
might be poorly assimilated and not contribute to effective
understanding, and parents clearly prefer to receive this infor-
mation before testing (142,146). Better parental education
about newborn screening for all disorders is vitally important
and ideally should occur in the prenatal setting (144–148).
Information should be provided in multiple formats (e.g., easy-
to-read pamphlets and videos) (149).
Obtaining parental permission might facilitate parental en-
gagement and education. Parental consent for newborn screen-
ing for PKU and other disorders has been debated since 1978
(150). Forty-eight states mandate newborn screening because
treatment begun soon after birth has been demonstrated to
prevent irreversible, devastating outcomes (e.g., death or se-
vere intellectual disability for certain disorders). When the
balance between benefits and risks for newborn screening tests
is not as dramatic as it is for PKU, the argument for parental
consent becomes more compelling (14,151).
Consent includes a spectrum of approaches, ranging from
providing information and obtaining verbal agreement to
written documentation of consent with a signature (152). A
report from an ad hoc Newborn Screening Task Force con-
vened in 1999 recommended that parents should be informed
and be able to refuse testing, although documentation of con-
sent should not be necessary (142). AAP has recommended
that states evaluate an informed consent process for newborn
screening tests to foster parental education and promote in-
formed responses to test results (144). Consent does not pre-
clude providers from making strong recommendations in favor
of testing, and if the risk is limited and clinical recommenda-
tions have been made to offer a test, the approach to consent
can be simple (153). In Massachusetts, where newborn screen-
ing for CF requires oral consent from a parent (i.e., a check
box on the newborn screening card indicates refusal), >98%
of parents consent to CF newborn screening (17).
Weighing Risks and Benefits
Evidence of Benefits
Health Outcomes
The 2003 workshop reviewed the U.S. and international
peer-reviewed medical literature to assess the efficacy of new-
born screening for CF in light of new data appearing since the
1997 workshop. The results support the efficacy of newborn
screening in reducing morbidity from CF (Table 4). In par-
ticular, the benefits of improved growth are now more clearly
established than in 1997, and the implications of growth re-
tardation for other clinical outcomes in CF are better under-
stood. In addition, benefits in terms of improved
patient-oriented outcomes, including cognitive outcomes,
hospitalizations, and survival, have been reported in recently
published studies. Unlike certain conditions for which uni-
versal newborn screening is mandated (e.g., PKU, congenital
hypothyroidism, and galactosemia), CF is not associated with
severe intellectual disability. For this reason, improvement in
cognitive scores, although meaningful, is not equivalent to
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prevention of mental retardation. Results of studies do not
demonstrate clear benefits on other important measures, in-
cluding HRQoL and pulmonary outcomes. No information
is available on cost-effectiveness, although partial cost analy-
ses have been published. Finally, newer research and the expe-
rience of additional cohorts with screening have tended to
alleviate concerns about risks of psychosocial harm among
children with CF but have continued to find evidence of anxi-
ety or misunderstanding among parents whose children have
false-positives results.
Growth and nutrition. As was true in 1997, the most clearly
defined benefit from newborn screening is improved growth
of affected children. In particular, the Wisconsin RCT pro-
vides strong evidence of long-term improvements in height-
for-age and reductions in chronic malnutrition. A second
analysis published in 2001 strengthened this finding by dem-
onstrating that the height advantage in the screened group
persisted through age >10 years and by including growth
measurements for a subset of the control group that had pre-
viously been excluded (77). In the SORT framework, a find-
ing from a single high-quality RCT that an intervention
substantially improves a patient-oriented outcome is consid-
ered to provide Level-1 evidence (Box 2). As a disease-ori-
ented outcome, evidence from an RCT is considered Level-3
evidence for recommendation of newborn screening for CF.
However, if height-for-age below the normal range were con-
sidered a patient-oriented outcome, this would be considered
Level-1 evidence. Studies in other countries also support im-
provements in height-for-age from screening for CF. In addi-
tion, anthropometric measures of nutritional status have been
linked to reduced mortality among children and adults with
CF independent of newborn screening, which suggests that
early initiation of nutritional therapies after newborn screen-
ing might lead to improved long-term survival (101).
Cognitive development. Newborn screening has also been
demonstrated to influence neurodevelopment positively in a
subset of children with CF. Results from the Wisconsin RCT
indicate moderate, clinically significant improvements in gen-
eral cognitive ability assessed in school-age children and ado-
lescents among those with vitamin E deficiency at time of
diagnosis (100). Assuming that a 12.5-point difference in cog-
nitive ability is considered a patient-oriented outcome, this
finding qualifies as Level-1 evidence in the SORT framework.
The observed overall difference of 5 points in mean cognitive
test scores between screened and control groups, which was
not statistically significant, is comparable in magnitude to that
associated with moderately elevated blood lead levels (154).
Other CF follow-up studies should conduct cognitive assess-
ments as well.
Hospitalization. Studies indicate a substantial benefit of
newborn screening in reducing the days of hospitalization for
children with CF, including one RCT from the United King-
dom (78) and observational studies from Australia (80), France
(87), the United Kingdom (91), and the United States (27).
A preliminary analysis of retrospectively collected data from
the Wisconsin RCT has not demonstrated this to be the case,
which might be attributable to how the data were collected or
to differences in treatment protocols. In addition to the po-
tential for newborn screening for CF to reduce costs to health-
care systems from hospitalizations, findings from Wisconsin
and Australia indicate health-care savings from reduced or-
dering of sweat tests ordered by primary care providers.
Survival. A number of observational studies and one RCT
have reported Level-2 evidence of proportional reductions  of
>50% in mortality rates among children with CF diagnosed
by newborn screening. Child mortality as a result of CF is low
in absolute terms (44), and the majority of the findings from
individual studies lack statistical significance. No studies have
reported equal or worse survival among screened children, al-
though the lack of negative findings might reflect publication
bias. A meta-analysis of survival data might provide more ro-
bust estimates of the effect on survival of newborn screening
for CF. In addition, the frequency of children with CF dying
without having received a diagnosis can be studied through
death records linked with stored residual blood spot speci-
mens from programs not screening for CF.
Pulmonary status. The effect of newborn screening on pul-
monary status among persons with CF as measured by chest
radiographs and lung function remains uncertain. Three ob-
servational studies, including two conducted in recent years,
have demonstrated evidence of less severe lung damage among
children identified by newborn screening, although no differ-
ence in lung function was demonstrated in two of the three
studies (Table 4). One cohort study from Australia reported
evidence of both better lung function and less lung damage
among children with CF born after screening was imple-
mented. Although the randomized Wisconsin trial identified
no benefit for any pulmonary measure through age 16 years
and a possible disadvantage in terms of chest radiographs, the
study was weakened by probable person-to-person transmis-
sion of P. aeruginosa in one clinic that did not segregate pa-
tients, thus possibly contaminating the results for this cohort.
In addition, the control group by chance had relatively more
subjects with pancreatic insufficiency and milder symptoms.
Even if the Wisconsin RCT had provided evidence of pulmo-
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nary benefit, this would be classified as Level-3 evidence in
the SORT framework, because it is a disease-oriented outcome.
HRQoL. Evidence of benefit is lacking for improved
HRQoL as a patient-oriented outcome measure for the effi-
cacy of newborn screening for CF. The Wisconsin study did
not identify significant differences in HRQoL between the
screened and control groups at age 7–14 years. The limited
literature on HRQoL relevant to CF suggests that differences
in HRQoL are related directly not to nutritional status or lung
function but primarily to the frequency of pulmonary exacer-
bations and treatment interventions, including hospitalization.
Distribution of benefits. For certain children detected
through screening, the benefits are more substantial than for
others. For example, greater growth is primarily of benefit to
those who would have been below the normal range in the
absence of screening. Similarly, the cognitive benefits from
screening are concentrated among those children at risk for
micronutrient deficiency. CF newborn screening is likely to
be most helpful for that subgroup of affected children who do
not receive a prompt diagnosis despite severe disease manifes-
tations. Benefits to this subset of children through screening
might not be reflected adequately in comparisons of mean
outcomes. Similarly, although child mortality as a result of
CF is low, early detection might save an infant from a rare
life-threatening event (e.g., hyponatremic dehydration). How-
ever, persons with pancreatic sufficiency, who comprise <10%
of persons with CF, might not benefit from newborn screen-
ing (4). Similarly, the 20% of persons with meconium ileus
do not appear to benefit from newborn screening because they
typically receive a diagnosis at birth.
Benefits to Families
In addition to health benefits for children, which are the
primary justification for newborn screening for CF, newborn
screening offers potential benefits to families. One such ben-
efit is the elimination of the diagnostic odyssey. Further, cer-
tain families value the genetic risk information received from
newborn screening for CF. Another benefit of carrier testing,
at least in the early years of newborn screening implementa-
tion, is the identification of older siblings who are symptom-
atic but have not received a diagnosis of CF after a positive
screen for CF in a newborn infant (140). Overall, studies re-
port that the majority of families of children who either screen
positive or receive a diagnosis of CF consider newborn screen-
ing for CF to be worthwhile.
Risks of Harms and Costs
The potential benefits of newborn screening programs
should be weighed against the potential harms and costs. Harm
from person-to-person transmission, which is not inherent to
earlier detection, can be avoided through involvement of new-
born screening programs with CF care centers and adoption
of infection control practices. The potential negative outcomes
of screening include effects from false-positive results and the
psychological and social effects of carrier identification for
parents and children. Studies indicate that certain parents ex-
perience anxiety from false-positive results and confusion over
the implications of CF carrier status.
Screening programs should explore options for minimizing
parental anxiety and misunderstanding. Concerns that should
be addressed include better communication of screening re-
sults and provision of more comprehensive information about
newborn screening. AAP has called for facilitating informed
parental choices regarding newborn screening (142,144).
Documentation of consent might not be necessary. The focus
should be on providing thorough, easily understood informa-
tion to parents about screening for CF and other conditions,
especially before delivery, to reduce misunderstanding and
provide parents with an opportunity to make informed choices,
consistent with state laws.
A full cost-effectiveness analysis of the costs and benefits of
newborn screening has not been conducted. Partial cost analy-
ses conducted in Wisconsin indicated that the majority of CF
screening costs in that state were offset by savings from the
reduction in the ordering of sweat tests (68,69). Other poten-
tial economic benefits are reductions in hospitalizations and
medications for screened children that have been reported,
although not in the Wisconsin study. Indeed, one of the ma-
jor benefits of newborn screening for CF might be to reduce
the level of treatments and costs needed to maintain compa-
rable health status between screened and unscreened children
(91,117). In the absence of formal economic evaluations, states
should assess the economic benefits of newborn screening for
CF compared with other alternative actions that might be fore-
gone if resources were allocated to CF screening (e.g., adding
another disorder to newborn screening panels).
Both risk and costs might be influenced by decisions about
testing methodology (e.g., IRT cutoffs and the numbers of
mutations included). As with all screening programs, a tradeoff
exists between sensitivity and specificity. Benefits can be maxi-
mized by identifying more children with CF (higher sensitiv-
ity), and risks can be reduced by decreasing the number of
carriers detected (higher specificity). Detecting more children
with CF by increasing the number of mutations tested for by
using the IRT/DNA approach necessarily increases the num-
ber of carriers detected. The Wisconsin program has reported
that switching from a single mutation to a 25-mutation panel
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raised screening costs by one third to one half but reduced the
frequency of false-negatives by more than half (Table 2) (69).
The potential for harms underscores the need for continual
monitoring and evaluation of screening outcomes to ensure
that children with CF benefit from screening and interven-
tions. An example is an evaluation by the Colorado newborn
screening program relative to P. aeruginosa acquisition (133).
Moreover, data collection and analysis are needed to evaluate
and optimize the performance of screening and diagnostic
algorithms (17).
Balance of Benefits and Risks
On the basis of the SORT taxonomy (Box 2) as applied in
this report, the evidence of health benefits merits a B-level
recommendation for newborn screening for CF. This is based
on evidence for several patient-oriented outcomes. This rec-
ommendation includes consistent Level-2 evidence for im-
proved child survival, although not all studies find statistically
significant differences. Although Level-2 evidence of benefit
in terms of reduced hospitalizations has also been reported
from multiple studies, the Wisconsin RCT provided incon-
sistent findings. One high-quality RCT has yielded positive
findings for two outcomes, growth and cognitive ability. Level-
1 evidence for cognitive outcome supports a B-level recom-
mendation. If impaired growth were classified as a
patient-oriented outcome, Level-1 evidence from the Wiscon-
sin RCT and Level-2 evidence from several observational stud-
ies would also provide support for a B-level recommendation.
On the basis of a preponderance of evidence, the health
benefits to children with CF outweigh the risk of harm and
justify screening for CF. The complex policy decision as to
whether to adopt screening also requires consideration of costs,
resources, and priorities (14). As a result, CDC believes that
including screening for CF in state newborn screening pro-
grams is justified. The evidence of clinical benefits from new-
born screening for CF is based on an extensive body of research,
including two RCTs and multiple prospective cohort studies.
Indeed, the CF research experience could be a model for de-
veloping an evidence base for use in assessing the risks and
benefits of other newborn screening tests (144).
The net balance of benefits and risks is contingent on how
newborn screening for CF is implemented (129). Conse-
quently, newborn screening programs for CF, if initiated,
should be of high quality and carefully monitored to ensure
consistent quality and effectiveness. CF screening programs
are complex and should be developed in a deliberate fashion
with attention to the experience of existing programs. Ben-
efits are likely to be maximized if children have access to state-
of-the-art therapy and follow-up with experienced
professionals. Adoption of newborn screening for CF should
be accompanied by an implementation planning process in-
volving specialized CF care centers and specialists in risk com-
munication, including genetic counselors. An implementation
plan should ensure that adequate personnel and other resources
required for the accurate diagnosis and clinical management of
young children with CF and the psychosocial and genetic coun-
seling needs of families with screen-positive infants are made
available to ensure effective and equitable access to services.
Recommendations
The magnitude of the health benefits from screening for
CF is sufficient that states should consider including routine
newborn screening for CF in conjunction with systems to
ensure access to high-quality care.
• In reaching a decision as to whether to add newborn
screening for CF, states should consider available state
resources and priorities as well as available national guide-
lines regarding CF screening, diagnosis, and treatment.
• States that implement newborn screening for CF should
collect follow-up data in collaboration with CF care cen-
ters and analyze this information to monitor and improve
the quality of CF newborn screening. In particular, states
should collect, share, and analyze data by using standard
protocols to evaluate and optimize laboratory algorithms
used to screen for CF and refer for diagnosis. States seek-
ing guidance on optimal laboratory protocols might wish
to consult with states having more experience in conduct-
ing CF screening of newborns.
• Newborn screening for CF should be accompanied by
rigorous infection control practices to minimize the risk
to children with CF detected at an early age of acquiring
infectious organisms associated with lung disease from
older patients. Further research is needed to evaluate and
optimize these practices.
• Newborn screening systems should ensure parental and
provider education and communication of screening re-
sults to primary-care providers in a manner that will en-
sure prompt referral to diagnostic centers. For CF, these
should be centers skilled in providing both sweat tests to
young, presymptomatic children with CF and accurate
and effective counseling to families, including those with
infants identified as carriers. States are recommended to
work with each other and with professional organizations
and federal agencies to develop approaches to provide
newborn screening information to parents during the pre-
natal and perinatal periods on all conditions, including
CF, to facilitate informed choices and appropriate
responses to positive screen results.
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AAP American Academy of Pediatrics
ACMG American College of Medical Genetics
allele alternative form of a gene that exists at
a specific gene location (locus) on a
chromosome
AMP adenosine-5’-monophosphate
analyte substance measured by a laboratory test
analytic validity ability of a test to accurately and reli-
ably measure a specific analyte or iden-
tify a mutation of interest, including
analytic sensitivity and specificity
anthropometry measurement of the size and propor-
tions of the human body and its parts
autosomal recessive allele located on one of the autosomal
chromosomes inherited from each par-
ent; presence of two similar alleles is
required to cause a particular clinical
finding or disorder
birth prevalence number of cases of a specified condi-
tion in a birth cohort relative to the
number of births
carrier person who has just one copy of a re-
cessive disease-causing allele; does not
have the disease in question
CF Cystic fibrosis
CFF Cystic Fibrosis Foundation
CFNPR Cystic Fibrosis Foundation National
Patient Registry
CFTR Cystic fibrosis transmembrane conduc-
tance regulator protein
CFTR gene that regulates expression of the
CFTR protein
CHQ Child Health Questionnaire; instru-
ment used to measure HRQoL
CI confidence interval
Terms and Abbreviations Used in This Report
clinical utility net balance of outcomes (risks, ben-
efits, and costs) demonstrated to result
from screening, including interven-
tions following diagnosis, in compari-
son to the natural history of the
disorder in the absence of screening
clinical validity ability of a test or protocol to accurately
and reliably identify individuals who
either have or will have the disorder or
phenotype of interest
CSI Cognitive Skills Index; measure of gen-
eral cognitive ability
failure to thrive restricted growth in weight and length
in an infant or toddler with unspeci-
fied cause
false-negative negative screening result reported for
a person who actually has the disease
of interest
false-positive positive screening result reported for a
person who does not have the disease
of interest
FEV1 forced expiratory volume in 1 second,
a measure of lung function
genotype a person’s genetic makeup, specifically
the alleles present at specific gene loci
height-for-age a person’s height relative to the heights
of others of the same age and sex in a
reference population
homozygote a person with two copies of the same
allele of a gene
HRQoL health-related quality of life
intent-to-treat analysis that classifies persons accord-
ing to the treatment that they were sup-
posed to have received rather than what
they actually experienced
IQR interquartile range (i.e., the range
between the 25th–75th percentiles)
IRT immunoreactive trypsinogen
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IRT/DNA screening protocol/algorithm in which
a blood spot specimen with an elevated
IRT value is tested for the presence of
CFTR mutations
IRT-repeat IRT screening protocol/algorithm in which
an infant with an elevated IRT on an
initial blood spot specimen has a sec-
ond specimen collected that is analyzed
for elevated IRT
lung function measures of flow of air out of the lungs
and how much air the lungs can hold
meconium ileus an intestinal obstruction present at
birth, due to abnormally thick meco-
nium that blocks the passage of stool
out of the ileum and into the colon
mutation a permanent heritable change in the
molecular sequence of a gene
newborn screening public health service for the early de-
tection of treatable disorders on the ba-
sis of laboratory analysis of dried blood
spot specimens collected from newborn
infants
nonclassic CF mild form of CF in which patients re-
tain CFTR and pancreatic function;
organ systems might be affected to a
lesser degree than in classic CF
pancreatic
insufficiency absence or virtual absence of pancre-
atic enzyme activity, resulting in re-
duced ability to digest and absorb fat
and fat-soluble vitamins
phenotype clinical presentation or expression of a
genotype
pilocarpine
iontophoresis activation of sweat glands on localized
area of skin by a positive electrode
moistened with pilocarpine nitrate; also
known as sweat testing
PKU phenylketonuria
positive predictive
value the likelihood that a person with a posi-
tive test result actually has the disease
QWB quality of well-being; instrument used
to measure HRQoL
RCT randomized controlled trial
RSV respiratory syncytial virus
SCD sickle cell disease
screen-positive person whose screening result is posi-
tive for a marker of a disease
screening algorithm clinical decision pathway involving a
series of screening tests and decision
points whether to refer for further
testing
SD standard deviation
sensitivity frequency with which a test yields a
positive result when the disease marker
or disease in question is actually present
in the person being tested
Shwachman score clinical score for CF with four sub-
scores: physical exam, nutrition, activ-
ity, and chest radiography
SORT Strength of Recommendation Tax-
onomy; a classification of types of evi-
dence for recommending clinical
interventions
specificity frequency with which a test yields a
negative result when the disease marker
or disease in question is not present in
the person being tested
spirometry method of quantifying flow of air out
of lungs by using mouthpiece attached
to a recording device
sweat testing collection and analysis of sweat elec-
trolytes to diagnose CF on the basis of
elevated sweat chloride levels
UKCFD United Kingdom Cystic Fibrosis
Database
USPSTF United States Preventive Services Task
Force
Z-score number of standard deviations by
which a measurement differs from the
mean of the reference distribution
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1. Cystic fibrosis is . . .
A. an autosomal recessive disorder.
B. a disorder associated with pulmonary disease.
C. a disorder associated with gastrointestinal disease.
D. not usually fatal in childhood.
E. all of the above.
2. Which of the following statements about newborn screening policy is
true in the United States?
A. Newborn screening is a federal responsibility.
B. Policymakers usually require evidence of cost-effectiveness for
newborn screening tests.
C. Newborn screening is implemented by states to prevent childhood
death, disability, or serious clinical complications.
D. Policymakers usually require randomized controlled trial data for
newborn screening tests.
3. Which of the following is not a newborn screening algorithm that is
used to refer infants for sweat testing in the United States?
A. Test two independent blood spot specimens from a newborn for
elevated immunoreactive trypsinogen (IRT).
B. Test a single blood spot specimen from each newborn for presence of
multiple cystic fibrosis transmembrane conductance regulator
(CFTR) gene mutations.
C. Test a single blood spot specimen from each newborn for elevated IRT
and multiple CFTR mutations.
D. Test a single blood spot specimen from each newborn for elevated IRT
and the common mutation, ∆F508.
4. Which of the following is true about the clinical diagnosis of CF?
A. Approximately 15% of children with CF have meconium ileus at birth.
B. Clinical symptoms in infants might be incorrectly attributed to
asthma.
C. The measurement of sweat chloride is the primary diagnostic test for
CF.
D. Children with signs of CF should receive diagnostic testing even if they
were screened as newborns.
E. All of the above are true.
5. The Wisconsin CF newborn screening project identified better
outcomes for the screened cohort in terms of . . .
A. lung function.
B. height-for-age ratios.
C. health-related quality of life.
D. survival.
E. B and D.
F. all of the above.
Goal and Objectives
This MMWR presents a framework for assessing the risks and benefits derived from newborn screening for cystic fibrosis (CF) and summarizes scientific evidence.
These recommendations were developed by CDC staff in collaboration with the Cystic Fibrosis Foundation. The goal of this report is to provide information for
policymakers and medical and public health professionals on which to base decisions regarding CF newborn screening programs. After completing this educational
activity, the reader should be able to 1) list patient-oriented outcomes that are relevant to evaluating the effectiveness of newborn screening for CF; 2) describe the
primary benefits of newborn screening for CF; 3) describe primary risks of newborn screening for CF; and 4) describe approaches to maximizing the benefit/risk ratio
of newborn screening for CF.
To receive continuing education credit, please answer all of the following questions.
6. Which potential benefit of newborn screening for CF has not received
support from the majority of observational studies that have examined
this outcome?
A. Growth.
B. Survival.
C. Lung function.
D. Reduced hospitalization.
7. Which of the following is not a psychosocial risk of either delayed
diagnosis or newborn screening?
A. Misunderstanding of carrier status.
B. Parental anxiety.
C. Parental frustration and mistrust.
D. Reduced medical bills.
8. What is the most serious risk of harm associated with newborn
screening for CF that has been reported in the scientific literature?
A. Earlier colonization with Pseudomonas aeruginosa.
B. Reduced access to private health insurance.
C. Premature death.
D. Impaired parental bonding.
9. Which best describes your professional activities?
A. Physician.
B. Nurse.
C. Health educator.
D. Office staff.
E. Other.
10. I plan to use these recommendations as the basis for . . .  (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
11. Each month, approximately how many patients with CF do you treat?
A. None.
B. 1–5.
C. 6–20.
D. 21–50.
E. 51–100.
F. >100.
12. How much time did you spend reading this report and completing the
exam?
A. <2.0 hours.
B. >2.0 hours but <3.0 hours.
C. >3.0 hours but <4.0.
D. >4.0 hours.
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13. After reading this report, I am confident I can list patient-oriented
outcomes that are relevant to evaluating the effectiveness of newborn
screening for CF.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
14. After reading this report, I am confident I can describe the primary
benefits of newborn screening for CF.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
15. After reading this report, I am confident I can describe primary risks
of newborn screening for CF.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can describe approaches to
maximizing the benefit/risk ratio of newborn screening for CF.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. The teaching strategies used in this report (text, boxes, figure, and
tables) were useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–8.
1. E.  2. C.  3. B.  4. E.  5. B.  6. C.  7. D.  8. A.
19. Overall, the presentation of the report enhanced my ability to
understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. The content of this activity was appropriate for my educational needs.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
22. The availability of continuing education credit influenced my
decision to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR subscription.
F. Other.
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